



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification <sup>6</sup> : <b>C12N 15/62, A61K 39/21, C07K 16/10, A61K 39/104, C12N 15/70, A61K 48/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/02713</b>
			(43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: <b>PCT/US98/14341</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 July 1998 (10.07.98)			
(30) Priority Data: 60/052,375 11 July 1997 (11.07.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/052,375 (CIP) Filed on 11 July 1997 (11.07.97)			
(71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Bethesda, MD 20892 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventor; and (75) Inventor/Applicant (for US only): FITZGERALD, David, J. [US/US]; 1202 Azalea Drive, Rockville, MD 20850 (US).			
(74) Agents: STORELLA, John, R. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).			

(54) Title: *PSEUDOMONAS* EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS

## (57) Abstract

This invention provides *Pseudomonas* exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of *Pseudomonas* exotoxin. Methods of eliciting an immune response using these immunogens also are provided.

**A** *Pseudomonas* exotoxin **B** V3-loop toxin chimera

**C**

Protein	Ib Loop Region Amino Acid Sequence	Molecular Mass
wild-type PE	-GAANADVSLTCPVAAGECAGPAD-	67,122 Da
ntPE-V3MN14	-GAANLHCGIHIGPGRAFYTTKCMQGPAD-	67,729 Da
ntPE-V3MN26	-GAANLHCNYNKRKRRIHIGPGRAFYTTKNIIGTICMQGPAD-	68,937 Da
ntPE-V3ThE26	-GAANLHCSNNTRTSITIGPGQVFYRTGDIIGDDICMQGPAD-	68,700 Da
ntPE-FP16	-GAANLQCRLEKKGNVVTDHRLCLQGPAD-	67,862 Da

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS

### CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of the filing date of co-pending application 60/052,375, filed July 11, 1997, the content of which is incorporated herein by reference in its entirety.

### BACKGROUND OF THE INVENTION

This invention is directed to the fields of chimeric proteins and immunology.

Immunization against infectious disease has been one of the great achievements of modern medicine. Vaccines can be useful only if the vaccine, itself, is not significantly pathogenic. Many vaccines are produced by inactivating the pathogen. For example, hepatitis vaccines can be made by heating the virus and treating it with formaldehyde. Other vaccines, for example certain polio vaccines, are produced by attenuating a live pathogen. However, there is concern about producing attenuated vaccines for certain infectious agents whose pathology is not fully understood, such as HIV.

Molecular biology has enabled the production of subunit vaccines; vaccines in which the immunogen is a fragment or subunit of a parent protein or complex.

Envelope proteins of HIV-1, such as gp120, are being evaluated as subunit vaccines. Several studies have suggested that antibodies to the V3 loop region of gp120 provide protection through virus neutralization. (Emini, E.A., *et al.*, 1992, *Nature* 355, 728-30; Javaherian, K., *et al.*, 1989, *Proc Natl Acad Sci USA* 86, 6768-72; Steimer, K.S., *et al.*, 1991, *Science* 254, 105-8; Wang, C.Y., *et al.*, 1991, *Science* 254, 285-8.)

However, subunit vaccines may not be complex enough to generate an appropriate immune response. Also, when the pathogen is highly mutable, as is HIV, subunit vaccines that elicit strain-specific immunity may not be effective in providing global protection. Furthermore, the injection of inactive virus or even the envelope

protein itself has the potential to produce a mixture of neutralizing and so-called "enhancing" antibodies. (Toth, F.D., *et al.*, 1994, *Clin Exp Immunol* 96, 389-94; Eaton, A.M., *et al.*, 1994, *Aids Res Hum Retroviruses* 10, 13-8; Mitchell, W.M., *et al.*, 1995, *Aids* 9, 27-34; Montefiori, D.C., *et al.*, 1996, *J Infect Dis* 173, 60-7.)

5           The immunogenicity of subunit vaccines is sometimes increased by coupling the subunit to a carrier protein to create a conjugate vaccine. One such carrier protein is *Pseudomonas* exotoxin A ("PE"). Investigators covalently linked a non-immunogenic O-polysaccharide derived from lipopolysaccharide ("LPS") to PE. The resulting conjugate vaccine elicited an immune response against both LPS and PE. (S.J. Cryz, Jr. *et al.* (1987) *J. Clin. Invest.*, 80:51-56 and S.J. Cryz, Jr. *et al.* (1990) *J. Infectious Diseases*, 163:1040-1045.) In another study, investigators were able to evoke an immune response against a *Plasmodium falciparum* antigen by coupling it through a spacer to PE. (J.U. Que *et al.* (1988) *Infection and Immunity*, 56:2645-49.) In a third study, investigators detoxified PE and chemically cross-linked it with principle  
10           neutralizing domain ("PND") peptides of HIV-1. The conjugate vaccine elicited the production of antibodies that recognized PND peptide and neutralized the homologous strain, HIV-1<sub>MN</sub>. (S.J. Cryz, Jr. *et al.* (1995) *Vaccine*, 13:66-71.)

          Chimeric proteins containing components of HIV-1 have been constructed and their immunogenic properties evaluated. These include: a poliovirus antigen  
20           containing an epitope of the gp41 transmembrane glycoprotein from HIV-1 (Evans, D.J., *et al.*, 1989, *Nature* 339, 385-8), a mucin protein containing multiple copies of the V3 loop (Fontenot, J.D., *et al.*, 1995, *Proc Natl Acad Sci USA*, 92, 315-9) a genetically modified cholera B chain with V3 loop sequences (Backstrom, M., *et al.*, 1994, *Gene* 149, 211-7) and a chemically detoxified PE-V3 loop peptide conjugate (Cryz, S., Jr., *et al.*, 1995, *Vaccine* 13, 67-71).  
25           

          The third variable (V3) loop of the envelope protein, gp120, contains the principal neutralizing domain of HIV-1. (Emini, E.A., *et al.*, 1992, *Nature* 355, 728-30; Javaherian, K., *et al.*, 1989, *Proc Natl Acad Sci USA* 86, 6768-72; Rusche, J.R., *et al.*, [published errata appear in *Proc Natl Acad Sci USA* 22, 8697 1988, and  
30           *Proc Natl Acad Sci USA* 5, 1667 1989, ]; *Proc Natl Acad Sci USA* 85, 3198-202 1988.) Although V3 loops vary considerably amongst the various HIV-1 strains (Berman, P.W., *et al.*, 1990, *Nature* 345, 622-5) specific antibodies to this region have been shown to neutralize infectivity of the virus and to prevent viral cell fusion *in vitro* (Kovacs, J.A.,



*et al.* 1993, *J. Clin Invest* 92, 919-28). Further, systemic immunization with a recombinant form of gp120 appears sufficient to protect chimpanzees from infection by HIV-1 systemic challenge. White-Scharf, M.E., *et al.*, 1993, *Virology* 192, 197-206.

HIV frequently gains entry to the body at mucosal surfaces. However, presently available HIV immunogens are not known to elicit a secretory immune response, which would inhibit viral access through the mucosa.

The development of a stable vaccine that could elicit both humoral and cellular responses, including mucosal immunity, and be flexible enough to incorporate sequences from many strains of an infectious agent, such as HIV-1, would be desirable.

## SUMMARY OF THE INVENTION

*Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogens in which a non-native epitope is inserted into the Ib domain are useful to elicit humoral, cell-mediated and secretory immune responses against the non-native epitope. In particular, the non-native epitope can be the V3 loop of the gp120 protein of HIV. Such chimeras are useful in vaccines against HIV infection.

PE chimeric immunogens offer several advantages. First, they can be made by wholly recombinant means. This eliminates the need to attach the epitope to PE by chemical cross-linking and to chemically inactivate the exotoxin. Recombinant technology also allows one to make a chimeric "cassette" having an insertion site for the non-native epitope of choice at the Ib domain location. This allows one to quickly insert existing variants of an epitope, or new variants of rapidly evolving epitopes. This enables production of vaccines that include a cocktail of different immunogens.

Second, *Pseudomonas* exotoxin can be engineered to alter the function of its domains, thereby providing a variety of activities. For example, by replacing the native cell binding domain of *Pseudomonas* exotoxin A (domain Ia) with a ligand for a particular cell receptor, one can target the chimera to bind to the particular cell type.

Third, because the Ib domain includes a cysteine-cysteine loop, epitopes that are so constrained in nature can be presented in near-native conformation. This assists in provoking an immune response against the native antigen. For example, a turn-turn-helix motif is evident with circular (constrained by a disulfide bond) but not linear peptides. (Ogata, M., *et al.*, 1990, *Biol Chem* 265, 20678-85.) Also, circular

peptides are recognized more readily by anti-V3 loop monoclonal antibodies than linear ones. (Catasti, P., *et. al.*, 1995, *J Biol Chem* 270, 2224-32.)

Fourth, the chimeras of this invention can be used to elicit a humoral, a cell-mediated or a secretory immune response. *Pseudomonas* exotoxin has been reported to act as a "superantigen," binding directly to MHC Class II molecules without prior processing in the antigen presenting cell. P.K. Legaard et al. (1991) *Cellular Immunology* 135:372-382. This promotes an MHC Class II-mediated immune response against cells bearing proteins containing the non-native epitope. Also, upon binding to a cell surface receptor, chimeric *Pseudomonas* exotoxins translocate into the cytosol. This makes possible an MHC Class I-dependent immune response against cells bearing the non-native epitope on their surface. This aspect is particularly advantageous because normally the immune system mounts an MHC Class I-dependent immune response only against proteins made by the cell. Also, by directing the chimera to a mucosal surface, one can elicit a secretory immune response involving IgA.

In one aspect, this invention provides a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that comprises a non-native epitope; and, optionally, (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence. In one embodiment, the chimeric immunogen comprises the amino acid sequence of a non-toxic PE wherein domain Ib further comprises the non-native epitope between two cysteine residues of domain Ib.

In certain embodiments the cell recognition domain binds to  $\alpha 2$ -macroglobulin receptor (" $\alpha 2$ -MR"), epidermal growth factor ("EGF") receptor, IL-2 receptor, IL-6 receptor, human transferrin receptor or gp120. In another embodiment, the cell recognition domain comprises amino acid sequences of a growth factor. In another embodiment, the translocation domain comprises amino acids 280 to 364 of domain II of PE. In another embodiment, the non-native epitope domain comprises a cysteine-cysteine loop that comprises the non-native epitope. In another embodiment, the non-native epitope domain comprises an amino acid sequence selected from the V3 loop

of HIV-1. In another embodiment, the ER retention domain is domain III of PE comprising a mutation that eliminates ADP ribosylation activity, such as  $\Delta$ E553. The ER retention domain can comprise the ER retention sequence REDLK (SEQ ID NO:11), REDL (SEQ ID NO:12) or KDEL (SEQ ID NO:13). In another embodiment the non-native epitope is an epitope from a pathogen (e.g., an epitope from a virus, bacterium or parasitic protozoa) or from a cancer antigen.

In another embodiment the cell recognition domain is domain Ia of PE, the translocation domain is domain II of PE, the non-native epitope domain comprises an amino acid sequence encoding a non-native epitope inserted between two cysteine residues of domain Ib of PE, and the ER retention domain is domain III of PE and comprises a mutation that eliminates ADP ribosylation activity.

In another aspect, this invention provides a recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen of this invention. In one embodiment, the recombinant polynucleotide is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

In another aspect, this invention provides a recombinant *Pseudomonas* exotoxin A-like chimeric immunogen cloning platform comprising a nucleotide sequence encoding: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence and, optionally, (4) a splicing site between the sequence encoding the translocation domain and the sequence encoding the ER retention domain. In one embodiment the recombinant polynucleotide is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

In another aspect this invention provides a method of producing antibodies against a non-native epitope naturally within a cysteine-cysteine loop. The method comprises the step of inoculating an animal with a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen of this invention wherein the non-native epitope domain comprises a cysteine-cysteine loop that comprises the non-native epitope.

In another aspect this invention provides a vaccine comprising at least one *Pseudomonas* exotoxin A-like chimeric immunogen comprising a cell recognition domain, a translocation domain, a non-native epitope domain comprising a non-native epitope and an endoplasmic reticulum ("ER") retention domain comprising an ER retention sequence. In one embodiment the vaccine comprises a plurality of PE-like chimeric immunogens, each immunogen having a different non-native epitope. In another embodiment the different non-native epitopes are epitopes of different strains of the same pathogen.

In another aspect this invention provides a method of eliciting an immune response against a non-native epitope in a subject. The method comprises the step of administering to the subject a vaccine comprising at least one *Pseudomonas* exotoxin A-like chimeric immunogen of this invention. In one embodiment, the non-native epitope comprises a binding motif for an MHC Class II molecule of the subject and the immune response elicited is an MHC Class-II dependent cell-mediated immune response. In another embodiment the non-native epitope comprises a binding motif for an MHC Class I molecule of the subject and the immune response elicited is an MHC Class-I dependent cell-mediated immune response.

In another aspect this invention provides a polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen of this invention.

In another aspect, this invention provides a method of eliciting an immune response against a non-native epitope in a subject. The method comprises the step of administering to the subject a polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen of this invention. In one embodiment, the recombinant polynucleotide is an expression vector comprising an expression control sequence operatively linked to the nucleotide sequence.

In another aspect this invention provides a method of eliciting an immune response against a non-native epitope in a subject, the method comprising the steps of transfecting cells with a recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen of this invention, and administering the cells to the subject.

In another aspect, this invention provides methods of eliciting an IgA-mediated secretory immune response. The methods involve administering to a mucosal membrane a non-toxic *Pseudomonas* chimeric immunogen of this invention, wherein the cell recognition domain binds to a receptor on a mucosal membrane. The cell  
5 recognition domain can bind to  $\alpha$ 2-MR (e.g., the native cell recognition domain of PE), or to the EGF receptor. The mucosal surface can be mouth, nose, lung, gut, vagina, colon or rectum.

In another aspect, this invention provides a composition comprising secretory IgA antibodies that specifically recognize an epitope of a pathogen that enters  
10 the body through a mucosal surface, e.g., an epitope of HIV-1.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figs 1A-1C. (A and B) A schematic depiction of PE and a PE-V3 loop chimera showing the relative location of the Ib and V3 loops between domains II and III. Approximate location of the single amino acid deletion ( $\Delta$ E553) to ablate PE toxicity is  
15 also shown. (C) Amino acid sequences, represented with single letter code, which replaced the Ib loop of wild-type PE with a V3 loop sequence of gp120 (bold type) from either the MN or Thai-E (TE) strains of HIV-1 contained two cysteine residues designed to result in a loop conformation following disulfide bond formation. The insertion of a  
20 unique PstI restriction site, used for introduction of V3 loop sequences, resulted in several modifications of the wild-type PE amino acid sequence adjacent to the Ib loop (italics). An irrelevant control peptide insert was prepared as a control and is designated ntPE-fp16. Calculated molecular masses are shown for full-length expressed proteins. Wild-type PE -- SEQ ID NO:6; ntPE-V3MN14 -- SEQ ID NO:7; ntPE-V3MN26 -- SEQ  
25 ID NO:8; ntPE-V3Th-E26 -- SEQ ID NO:9; ntPE-fp16 -- SEQ ID NO:10.

Figs 2A-2C. Characterization of ntPE-V3 loop chimeras after separation by SDS-PAGE. (A) Coomassie blue staining of purified ntPE-V3 loop chimeras following separation by SDS-PAGE. Approximately 1  $\mu$ g of protein was loaded on each lane. (B) Western blot analysis of ntPE-V3 loop chimeras. After transfer to Immobilon P  
30 membranes, proteins were probed with monoclonal antibodies raised against intact gp120/MN (1F12) or gp120/Thai-E (1B2). An irrelevant sequence of 16 amino adds was inserted into the Ib loop region of ntPE (ntPE-fp16) and was used here as a negative control. (C) Immunocapture studies, using either 1F12 or 1B2 immobilized on protein G

sepharose, were used to characterize the exposure of V3 loop sequences on the surface of the various chimeric proteins. Proteins were visualized by staining gels with Coomassie blue. Gp120 and ntPE-fp16 were used as positive and negative controls respectively. The capture of PE-V3 loop proteins is indicated with a single arrowhead and of gp120 by a double arrowhead. The left panel shows the presence of the antibody heavy chain (hc) only since the light chain (lc) was run off the gel. The right panel shows both chains.

Figs. 3A-3C. V3 loop amino acid sequence insertions do not significantly alter the secondary structure of wild-type PE. Near UV (A) and far UV (B) CD spectra (mean of three scans following background spectrum subtraction) were digitally smoothed, corrected for concentration, and normalized to units of mean residue weight ellipticity. (C) Secondary structure calculations were performed using the SELCON fitting program. \*Calculated  $\alpha$ -helix content agrees with values determined from changes in observed ellipticity at 222 nm.

Fig. 4. Toxic PE-V3 loop chimeras affect cell survival. The extent of protein synthesis, assessed by  $^3\text{H}$ -leucine incorporation, was determined in human A431 cells following 18 h of exposure to various concentrations of either wild-type PE or a toxic form (with a glutamic acid residue at position 553 and capable of ADP ribosylating elongation factor 2) of PE-V3MN26.

Figs 5A-5B. Characterization of rabbit sera following immunization with either ntPE-V3MN26 or ntPE-V3Th-E26. (A) Western blot reactivity of rabbit antisera diluted 1:1000 for recombinant gp120/MN and gp120/Th-E was assessed following SDS-PAGE and the transfer of proteins to Immobilon P membranes. Reactive primary antibody was detected by a secondary anti-rabbit antibody conjugated to horseradish peroxidase. (B) Rabbit sera obtained from animals injected with ntPE-V3MN26 was pre-incubated with competing soluble gp120/MN at concentrations up to 50  $\mu\text{g}/\text{ml}$ . Residual reactivity was detected by Western blot analysis of immobilized gp120/MN as described for (A).

Fig. 6. A ntPE-V3 loop chimera administered to rabbits produces an antibody response capable of neutralizing HIV-1 infectivity *in vitro*. Rabbits were immunized subcutaneously with 200  $\mu\text{g}$  ntPE-V3MN26 and boosted similarly after 2, 4 and 12 weeks. Sera collected up to 27 weeks after the initial administration were evaluated for the ability to protect a human T-cell line, MT4, from killing by HIV-1 MN

as assessed by an MTT dye conversion assay. Values represent triplicate readings normalized against a control MT4 incubation not challenged by virus.

Fig. 7 is a diagram of *Pseudomonas* Exotoxin A structure. The amino acid position based on SEQ ID NO:2 is indicated. Domain 1a extends from amino acids 1-252. Domain II extends from amino acids 253-364. It includes a cysteine-cysteine loop formed by cysteines at amino acids 265-287. Furin cleaves within the cysteine-cysteine loop between amino acids 279 and 280. A fragment of PE beginning with amino acid 280 translocates to the cytosol. Constructs in which amino acids 345-364 are eliminated also translocate. Domain Ib spans amino acids 365-399. It contains a cysteine-cysteine loop formed by cysteines at amino acids 372 and 379. The domain can be eliminated entirely. Domain III spans amino acids 400-613. Deletion of amino acid 553 eliminates ADP ribosylation activity. The endoplasmic reticulum sequence, REDLK (SEQ ID NO:11) is located at the carboxy-terminus of the molecule, from amino acid 609-613.

Fig. 8 demonstrates that PE-V3 loop chimeras are trafficked similarly to native PE. Confluent monolayers of Caco-2 cells were exposed apically to recombinant, enzymatically-active *Pseudomonas* exotoxin (rEA-PE). Cell killing produced by 24 h of exposure at various native PE (rEA-PE) concentrations were compared to that produced by similar treatment with enzymatically-active versions of PE chimeras containing either 14 or 26 amino acids of the V3 loop of HIV-1 MNgp120.

Fig. 9 demonstrates that PE-V3 loop chimeras induce a serum IgG response. A non-toxic (enzymatically inactive) V3 loop chimera containing 26 amino acids of the V3 loop of HIV-1 MNgp120 (PEMN26) was administered to rabbits through six different inoculation protocols. Serum samples drawn at the times described were assayed by ELISA for MNgp120-specific IgG using a monoclonal antibody (1F12) which recognizes the V3 loop of this protein for assay calibration.

Fig. 10 shows that PE-V3 loop chimeras induce a salivary IgA response. A non-toxic (enzymatically inactive) V3 loop chimera containing 26 amino acids of the V3 loop of HIV-1 MNgp120 (PEMN26) was administered to rabbits through six different inoculation protocols. Saliva samples obtained following pilocarpine administration at the times described were assayed by ELISA for MNgp120-specific IgA. No gp120-specific IgA antibody was available for assay calibration. Values are reported as values normalized to a standardized positive sample.

Fig. 11 shows relative levels of salivary IgA following mucosal or systemic inoculation with ntPE-V3MN26. MN-gp120 specific IgA antibodies were measured by ELISA in saliva samples, normalized against a strongly positive sample and reported on an arbitrary scale of one antigen-specific IgA unit.

Fig. 12 shows serum levels of IgG following mucosal or systemic inoculation with ntPE-V3MN26. MN-gp120 specific IgG antibodies were measured in serum samples by ELISA and standardized against a mouse monoclonal antibody which specifically recognizes the V3 loop of MNgp120.

Fig. 13 shows serum levels of IgG following subcutaneous injection of ntPE-V3MN26. The immune response produced from injection of ntPE-V3MN26 (hatched bars) was compared to that induced when co-injected with a regimen of Freund's complete and incomplete adjuvant (solid bars). Non-toxic PE not containing the 26 amino acids from the V3 loop of MNgp120 was injected with the same adjuvant regimen as a control. MN-gp120 specific IgG antibodies were measured in serum samples by ELISA and standardized against a mouse monoclonal antibody which specifically recognizes the V3 loop of MNgp120.

Figs. 14A and 14B shows neutralization of clinical HIV isolates with antibodies elicited with the chimeric immunogens of this invention. Postvaccination sera from rabbits injected with ntPE-V3MN26 were mixed with either a B (Fig. 14A) or E (Fig. 14B) subtype virus. After a 1-h incubation at 37° C, viral infectivity was determined by adding treated virus to PBMCs for another 3 days. Inhibition of viral growth was evaluated by measuring p24 levels. Open square: p24 antigen (uninfected); closed circle: p24 antigen 1 prebleed sera; open circle: p24 antigen 1 immune sera (24 weeks).

## DETAILED DESCRIPTION OF THE INVENTION

### I. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., *DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY* (2d ed. 1994); *THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY* (Walker ed., 1988); *THE GLOSSARY OF*



GENETICS, 5TH ED., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY (1991). As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

"Polynucleotide" refers to a polymer composed of nucleotide units.

5 Polynucleotides include naturally occurring nucleic acids, such as deoxyribonucleic acid ("DNA") and ribonucleic acid ("RNA") as well as nucleic acid analogs. Nucleic acid analogs include those which include non-naturally occurring bases, nucleotides that engage in linkages with other nucleotides other than the naturally occurring phosphodiester bond or which include bases attached through linkages other than  
10 phosphodiester bonds. Thus, nucleotide analogs include, for example and without limitation, phosphorothioates, phosphorodithioates, phosphorotriesters, phosphoramidates, boranophosphates, methylphosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), and the like. Such polynucleotides can be synthesized, for example, using an automated DNA synthesizer. The term "nucleic acid"  
15 typically refers to large polynucleotides. The term "oligonucleotide" typically refers to short polynucleotides, generally no greater than about 50 nucleotides. It will be understood that when a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), this also includes an RNA sequence (i.e., A, U, G, C) in which "U" replaces "T."

20 "cDNA" refers to a DNA that is complementary or identical to an mRNA, in either single stranded or double stranded form.

Conventional notation is used herein to describe polynucleotide sequences: the left-hand end of a single-stranded polynucleotide sequence is the 5'-end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5'-direction.  
25 The direction of 5' to 3' addition of nucleotides to nascent RNA transcripts is referred to as the transcription direction. The DNA strand having the same sequence as an mRNA is referred to as the "coding strand"; sequences on the DNA strand having the same sequence as an mRNA transcribed from that DNA and which are located 5' to the 5'-end of the RNA transcript are referred to as "upstream sequences"; sequences on the DNA  
30 strand having the same sequence as the RNA and which are 3' to the 3' end of the coding RNA transcript are referred to as "downstream sequences."

"Complementary" refers to the topological compatibility or matching together of interacting surfaces of two polynucleotides. Thus, the two molecules can be

described as complementary, and furthermore, the contact surface characteristics are complementary to each other. A first polynucleotide is complementary to a second polynucleotide if the nucleotide sequence of the first polynucleotide is identical to the nucleotide sequence of the polynucleotide binding partner of the second polynucleotide.

5 Thus, the polynucleotide whose sequence 5'-TATAC-3' is complementary to a polynucleotide whose sequence is 5'-GTATA-3'.

A nucleotide sequence is "substantially complementary" to a reference nucleotide sequence if the sequence complementary to the subject nucleotide sequence is substantially identical to the reference nucleotide sequence.

10 "Encoding" refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus,  
15 a gene encodes a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and non-coding strand, used as the template for transcription, of a gene or cDNA can be referred to as encoding the protein or other product of that gene or  
20 cDNA. Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.

"Recombinant polynucleotide" refers to a polynucleotide having sequences  
25 that are not naturally joined together. An amplified or assembled recombinant polynucleotide may be included in a suitable vector, and the vector can be used to transform a suitable host cell. A host cell that comprises the recombinant polynucleotide is referred to as a "recombinant host cell." The gene is then expressed in the recombinant host cell to produce, e.g., a "recombinant polypeptide." A recombinant  
30 polynucleotide may serve a non-coding function (e.g., promoter, origin of replication, ribosome-binding site, etc.) as well.

"Expression control sequence" refers to a nucleotide sequence in a polynucleotide that regulates the expression (transcription and/or translation) of a

nucleotide sequence operatively linked thereto. "Operatively linked" refers to a functional relationship between two parts in which the activity of one part (e.g., the ability to regulate transcription) results in an action on the other part (e.g., transcription of the sequence). Expression control sequences can include, for example and without  
5 limitation, sequences of promoters (e.g., inducible or constitutive), enhancers, transcription terminators, a start codon (i.e., ATG), splicing signals for introns, and stop codons.

"Expression vector" refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide  
10 sequence to be expressed. An expression vector comprises sufficient *cis*-acting elements for expression; other elements for expression can be supplied by the host cell or *in vitro* expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses that incorporate the recombinant polynucleotide.

15 "Amplification" refers to any means by which a polynucleotide sequence is copied and thus expanded into a larger number of polynucleotide molecules, e.g., by reverse transcription, polymerase chain reaction, and ligase chain reaction.

"Primer" refers to a polynucleotide that is capable of specifically hybridizing to a designated polynucleotide template and providing a point of initiation for  
20 synthesis of a complementary polynucleotide. Such synthesis occurs when the polynucleotide primer is placed under conditions in which synthesis is induced, i.e., in the presence of nucleotides, a complementary polynucleotide template, and an agent for polymerization such as DNA polymerase. A primer is typically single-stranded, but may be double-stranded. Primers are typically deoxyribonucleic acids, but a wide variety of  
25 synthetic and naturally occurring primers are useful for many applications. A primer is complementary to the template to which it is designed to hybridize to serve as a site for the initiation of synthesis, but need not reflect the exact sequence of the template. In such a case, specific hybridization of the primer to the template depends on the stringency of the hybridization conditions. Primers can be labeled with, e.g.,  
30 chromogenic, radioactive, or fluorescent moieties and used as detectable moieties.

"Probe," when used in reference to a polynucleotide, refers to a polynucleotide that is capable of specifically hybridizing to a designated sequence of another polynucleotide. A probe specifically hybridizes to a target complementary

polynucleotide, but need not reflect the exact complementary sequence of the template. In such a case, specific hybridization of the probe to the target depends on the stringency of the hybridization conditions. Probes can be labeled with, e.g., chromogenic, radioactive, or fluorescent moieties and used as detectable moieties.

5           A first sequence is an "antisense sequence" with respect to a second sequence if a polynucleotide whose sequence is the first sequence specifically hybridizes with a polynucleotide whose sequence is the second sequence.

          "Hybridizing specifically to" or "specific hybridization" or "selectively hybridize to", refers to the binding, duplexing, or hybridizing of a nucleic acid molecule  
10           preferentially to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.

          The term "stringent conditions" refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences. "Stringent hybridization" and "stringent hybridization wash  
15           conditions" in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular  
20           Biology--Hybridization with Nucleic Acid Probes* part I chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very  
25           stringent conditions are selected to be equal to the T<sub>m</sub> for a particular probe.

          An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formalin with 1 mg of heparin at 42° C, with the hybridization being carried out overnight. An example of highly stringent wash  
30           conditions is 0.15 M NaCl at 72° C for about 15 minutes. An example of stringent wash conditions is a 0.2X SSC wash at 65° C for 15 minutes (see, Sambrook et al. for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency

wash for a duplex of, e.g., more than 100 nucleotides, is 1x SSC at 45° C for 15 minutes. An example low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4-6x SSC at 40° C for 15 minutes. In general, a signal to noise ratio of 2x (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

"Polypeptide" refers to a polymer composed of amino acid residues, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof linked via peptide bonds, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer. The term "protein" typically refers to large polypeptides. The term "peptide" typically refers to short polypeptides.

Conventional notation is used herein to portray polypeptide sequences: the left-hand end of a polypeptide sequence is the amino-terminus; the right-hand end of a polypeptide sequence is the carboxyl-terminus.

"Conservative substitution" refers to the substitution in a polypeptide of an amino acid with a functionally similar amino acid. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

"Allelic variant" refers to any of two or more polymorphic forms of a gene occupying the same genetic locus. Allelic variations arise naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. "Allelic variants" also refer to cDNAs derived from mRNA transcripts of genetic allelic variants, as well as the proteins encoded by them.

The terms "identical" or percent "identity," in the context of two or more polynucleotide or polypeptide sequences, refer to two or more sequences or subsequences

that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.

5                   The phrase "substantially identical," in the context of two nucleic acids or polypeptides, refers to two or more sequences or subsequences that have at least 60%, 80%, 90%, 95% or 98% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists  
10 over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues. In a most preferred embodiment, the sequences are substantially identical over the entire length of the coding regions.

15                   For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence  
20 identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443  
25 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (*see generally* Ausubel *et al.*, *supra*).

30                   One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP

uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or

the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP  
5 program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (*see, e.g.,*  
10 Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a  
15 comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid,  
20 as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described herein.

25 A "ligand" is a compound that specifically binds to a target molecule.

A "receptor" is compound that specifically binds to a ligand.

"Antibody" refers to a polypeptide ligand substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically binds and recognizes an epitope (e.g., an antigen). The recognized immunoglobulin  
30 genes include the kappa and lambda light chain constant region genes, the alpha, gamma, delta, epsilon and mu heavy chain constant region genes, and the myriad immunoglobulin variable region genes. Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterized fragments produced by digestion with various peptidases. This



includes, e.g., Fab' and F(ab)'<sub>2</sub> fragments. The term "antibody," as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies. It also includes polyclonal antibodies, monoclonal antibodies, chimeric antibodies and humanized antibodies. "Fc" portion of an antibody refers to that portion of an immunoglobulin heavy chain that comprises one or more heavy chain constant region domains, CH<sub>1</sub>, CH<sub>2</sub> and CH<sub>3</sub>, but does not include the heavy chain variable region.

A ligand or a receptor (e.g., an antibody) "specifically binds to" or "is specifically immunoreactive with" a compound analyte when the ligand or receptor functions in a binding reaction which is determinative of the presence of the analyte in a sample of heterogeneous compounds. Thus, under designated assay (e.g., immunoassay) conditions, the ligand or receptor binds preferentially to a particular analyte and does not bind in a significant amount to other compounds present in the sample. For example, a polynucleotide specifically binds under hybridization conditions to an analyte polynucleotide comprising a complementary sequence; an antibody specifically binds under immunoassay conditions to an antigen analyte bearing an epitope against which the antibody was raised; and an adsorbent specifically binds to an analyte under proper elution conditions.

"Immunoassay" refers to a method of detecting an analyte in a sample involving contacting the sample with an antibody that specifically binds to the analyte and detecting binding between the antibody and the analyte. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

"Vaccine" refers to an agent or composition containing an agent effective to confer a therapeutic degree of immunity on an organism while causing only very low levels of morbidity or mortality. Methods of making vaccines are, of course, useful in the study of the immune system and in preventing and treating animal or human disease.

An "immunogenic amount" is an amount effective to elicit an immune response in a subject.

"Substantially pure" or "isolated" means an object species is the predominant species present (i.e., on a molar basis, more abundant than any other individual macromolecular species in the composition), and a substantially purified fraction is a composition wherein the object species comprises at least about 50% (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition means that about 80% to 90% or more of the macromolecular species present in the composition is the purified species of interest. The object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) if the composition consists essentially of a single macromolecular species. Solvent species, small molecules (< 500 Daltons), stabilizers (e.g., BSA), and elemental ion species are not considered macromolecular species for purposes of this definition.

"Naturally-occurring" as applied to an object refers to the fact that the object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring.

"Detecting" refers to determining the presence, absence, or amount of an analyte in a sample, and can include quantifying the amount of the analyte in a sample or per cell in a sample.

"Detectable moiety" or a "label" refers to a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include  $^{32}\text{P}$ ,  $^{35}\text{S}$ , fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin-streptavidin, dioxigenin, haptens and proteins for which antisera or monoclonal antibodies are available, or nucleic acid molecules with a sequence complementary to a target. The detectable moiety often generates a measurable signal, such as a radioactive, chromogenic, or fluorescent signal, that can be used to quantitate the amount of bound detectable moiety in a sample. The detectable moiety can be incorporated in or attached to a primer or probe either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., incorporation of radioactive nucleotides, or biotinylated nucleotides that are recognized by streptavidin. The detectable moiety may be directly or indirectly detectable. Indirect detection can involve the binding of a second directly or indirectly detectable moiety to the detectable

moiety. For example, the detectable moiety can be the ligand of a binding partner, such as biotin, which is a binding partner for streptavidin, or a nucleotide sequence, which is the binding partner for a complementary sequence, to which it can specifically hybridize. The binding partner may itself be directly detectable, for example, an antibody may be itself labeled with a fluorescent molecule. The binding partner also may be indirectly detectable, for example, a nucleic acid having a complementary nucleotide sequence can be a part of a branched DNA molecule that is in turn detectable through hybridization with other labeled nucleic acid molecules. (See, e.g., PD. Fahrlander and A. Klausner, *Bio/Technology* (1988) 6:1165.) Quantitation of the signal is achieved by, e.g., scintillation counting, densitometry, or flow cytometry.

"Linker" refers to a molecule that joins two other molecules, either covalently, or through ionic, van der Waals or hydrogen bonds, e.g., a nucleic acid molecule that hybridizes to one complementary sequence at the 5' end and to another complementary sequence at the 3' end, thus joining two non-complementary sequences.

"Pharmaceutical composition" refers to a composition suitable for pharmaceutical use in a mammal. A pharmaceutical composition comprises a pharmacologically effective amount of an active agent and a pharmaceutically acceptable carrier. "Pharmacologically effective amount" refers to that amount of an agent effective to produce the intended pharmacological result. "Pharmaceutically acceptable carrier" refers to any of the standard pharmaceutical carriers, buffers, and excipients, such as a phosphate buffered saline solution, 5% aqueous solution of dextrose, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents and/or adjuvants. Suitable pharmaceutical carriers and formulations are described in *Remington's Pharmaceutical Sciences*, 19th Ed. (Mack Publishing Co., Easton, 1995). Preferred pharmaceutical carriers depend upon the intended mode of administration of the active agent. Typical modes of administration include enteral (e.g., oral) or parenteral (e.g., subcutaneous, intramuscular, intravenous or intraperitoneal injection; or topical, transdermal, or transmucosal administration). A "pharmaceutically acceptable salt" is a salt that can be formulated into a compound for pharmaceutical use including, e.g., metal salts (sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.

"Small organic molecule" refers to organic molecules of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes organic

biopolymers (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, up to about 2000 Da, or up to about 1000 Da.

A "subject" of diagnosis or treatment is a human or non-human animal, including a mammal or a primate.

5 "Treatment" refers to prophylactic treatment or therapeutic treatment.

A "prophylactic" treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology.

10 A "therapeutic" treatment is a treatment administered to a subject who exhibits signs of pathology for the purpose of diminishing or eliminating those signs.

"Diagnostic" means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their specificity and selectivity. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it suffices if the method provides a positive indication that aids in diagnosis.

15 "Prognostic" means predicting the probable development (e.g., severity) of a pathologic condition.

"Plurality" means at least two.

20 "Pseudomonas exotoxin A" or "PE" is secreted by *Ps aeruginosa* as a 67 kD protein composed of three prominent globular domains (Ia, II, and III) and one small subdomain (Ib) connecting domains II and III. (A.S. Allured et. al. (1986) *Proc. Natl. Acad. Sci.* 83:1320-1324.) Domain Ia of PE mediates cell binding. In nature, domain Ia binds to the low density lipoprotein receptor-related protein ("LRP"), also known as the  $\alpha$ 2-macroglobulin receptor (" $\alpha$ 2-MR"). (M.Z. Kounnas et al. (1992) *J. Biol. Chem.* 267:12420-23.) It spans amino acids 1-252. Domain II mediates translocation to the  
25 cytosol. It spans amino acids 253-364. Domain Ib has no known function. It spans amino acids 365-399. Domain III is responsible for cytotoxicity and includes an endoplasmic reticulum retention sequence. It mediates ADP ribosylation of elongation factor 2, which inactivates protein synthesis. It spans amino acids 400-613. PE is "non-toxic" if it lacks EF2 ADP ribosylation activity. Deleting amino acid E553 (" $\Delta$ E553")  
30 from domain III detoxifies the molecule. PE having the mutation  $\Delta$ E553 is referred to herein as "PE  $\Delta$ E553." Genetically modified forms of PE are described in, e.g., Pastan et al., United States patent 5,602,095; Pastan et al., United States patent 5,512,658 and Pastan et al., United States patent 5,458,878. Allelic forms of PE are included in this

definition. See, e.g., M.L. Vasil *et al.*, (1986) *Infect. Immunol.* 52:538-48.

"Cysteine-cysteine loop" refers to a peptide moiety in a polypeptide that is defined by an amino acid sequence bordered by two disulfide-bonded cysteine residues.

5 "Non-native epitope" refers to an epitope encoded by an amino acid sequence that does not naturally occur in the Ib domain of *Pseudomonas* exotoxin A.

## II. PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS

### A. Basic Structure

10 The *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogens of this invention are polypeptides having structural domains organized, except as provided herein, in the same sequence as the four structural domains of PE (i.e., Ia, II, Ib and III), and having certain functions (e.g., cell recognition, cytosolic translocation and endoplasmic reticulum retention) also possessed by the functional domains of PE. Additionally, the PE-like chimeric immunogens of this invention possess a domain that  
15 functionalizes a domain of PE for which no function yet has been identified. Namely, PE-like chimeric immunogens replace the Ib domain of PE with a functional non-native epitope domain that serves as an immunogen to elicit an immune response against the non-native epitope.

20 Accordingly, PE-like chimeric immunogens include the following structural domains comprised of amino acid sequences, the domains imparting particular functions to the chimeric protein: (1) a "cell recognition domain" that functions as a ligand for a cell surface receptor and that mediates binding of the protein to a cell; (2) a "translocation domain" that mediates translocation from the endosomes to the cytosol; (3)  
25 a "non-native epitope domain" that contains the immunogenic non-native epitope; and, optionally, (4) an "endoplasmic reticulum ("ER") retention domain" that functions to translocate the molecule from the endosome to the endoplasmic reticulum, from which it enters the cytosol. When the ER retention domain is eliminated the chimeric immunogen still can retain immunogenic function.

30 In one embodiment, a PE-like chimeric immunogen comprises the native sequence of PE, except for the Ib domain, which is engineered to include the amino acid sequence of a non-native epitope. For example, one can insert an amino acid sequence encoding the non-native epitope into the cysteine-cysteine loop of the Ib domain.

However, the relationship of PE structure to its function has been extensively studied. The amino acid sequence of PE has been re-engineered to provide new functions, and many amino acids or peptide segments critical and non-critical to PE function have been identified. The PE-like chimeric immunogens of this invention can incorporate these structural modifications to PE.

#### B. Cell Recognition Domain

The *Pseudomonas* exotoxin chimeras of this invention comprise an amino acid sequence encoding a "cell recognition domain." The cell recognition domain functions as a ligand for a cell surface receptor. It mediates binding of the protein to a cell. Its purpose is to target the chimera to a cell which will transport it to the cytosol for processing. The cell recognition domain can be located in the position of domain Ia of PE. However, this domain can be moved out of the normal organizational sequence. More particularly, the cell recognition domain can be inserted upstream of the ER retention domain. Alternatively the cell recognition domain can be chemically coupled to the toxin. Also, the chimera can include a first cell recognition domain at the location of the Ia domain and a second cell recognition domain upstream of the ER retention domain. Such constructs can bind to more than one cell type. See, e.g., R.J. Kreitman *et al.* (1992) *Bioconjugate Chem.* 3:63-68.

Because the cell recognition domain functions as a handle to attach the chimera to a cell, it can have the structure of any polypeptide known to bind to a particular receptor. Accordingly, the domain generally has the size of known polypeptide ligands, e.g., between about 10 amino acids and about 1500 amino acids, or about 100 amino acids and about 300 amino acids.

Several methods are useful for identifying functional cell recognition domains for use in chimeric immunogens. One method involves detecting binding between a chimera that comprises the cell recognition domain with the receptor or with a cell bearing the receptor. Other methods involve detecting entry of the chimera into the cytosol, indicating that the first step, cell binding, was successful. These methods are described in detail below in the section on testing.

The cell recognition domain can have the structure of any polypeptide that binds to a cell surface receptor. In one embodiment, the amino acid sequence is that of domain Ia of PE, thereby targeting the chimeric protein to the  $\alpha 2$ -MR domain. In other

embodiments domain Ia can be substituted with: growth factors, such as TGF $\alpha$ , which binds to epidermal growth factor ("EGF"); IL-2, which binds to the IL-2 receptor; IL-6, which binds to the IL-6 receptor (e.g., activated B cells and liver cells); CD4, which binds to HIV-infected cells); a chemokine (e.g., Rantes, MIP-1 $\alpha$  or MIP-1 $\beta$ ), which binds to a chemokine receptor (e.g., CCR5 or fusin (CXCR4)); ligands for leukocyte cell surface receptors, for example, GM-CSF, G-CSF; ligands for the IgA receptor; or antibodies or antibody fragments directed to any receptor (e.g., single chain antibodies against human transferrin receptor). I. Pastan *et al.* (1992) *Annu. Rev. Biochem.* 61:331-54.

In one embodiment, the cell recognition domain is located in place of domain Ia of PE. It can be attached to the other moiety of the molecule through a linker. However, engineering studies show that *Pseudomonas* exotoxin can be targeted to certain cell types by introducing a cell recognition domain upstream of the ER retention sequence, which is located at the carboxy-terminus of the polypeptide. For example, TGF $\alpha$  has been inserted into domain III just before amino acid 604, i.e., about ten amino acids from the carboxy-terminus. This chimeric protein binds to cells bearing EGF receptor. Pastan *et al.*, U.S. Patent 5,602,095.

Cell specific ligands which are proteins can often be formed in part or in whole as a fusion protein with the *Pseudomonas* exotoxin chimeras of the present invention. A "fusion protein" refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed by the amino terminus of one polypeptide and the carboxyl terminus of the other polypeptide. The fusion protein may be formed by the chemical coupling of the constituent polypeptides but is typically expressed as a single polypeptide from a nucleic acid sequence encoding the single contiguous fusion protein. Included among such fusion proteins are single chain Fv fragments (scFv). Particularly preferred targeted *Pseudomonas* exotoxin chimeras are disulfide stabilized proteins which can be formed in part as a fusion protein as exemplified herein. Other protein cell specific ligands can be formed as fusion proteins using cloning methodologies well known to the skilled artisan.

Attachment of cell specific ligands also can be accomplished through the use of linkers. The linker is capable of forming covalent bonds or high-affinity non-covalent bonds to both molecules. Suitable linkers are well known to those of ordinary skill in the art and include, but are not limited to, straight or branched-chain

carbon linkers, heterocyclic carbon linkers, or peptide linkers. The linkers may be joined to the constituent amino acids through their side groups (*e.g.*, through a disulfide linkage to cysteine).

In one embodiment, domain Ia is replaced with a polypeptide sequence for an immunoglobulin heavy chain from an immunoglobulin specific for the target cell. The light chain of the immunoglobulin can be co-expressed with the PE-like chimeric immunogen so as to form a light chain-heavy chain dimer. In the conjugate protein, the antibody is chemically linked to a polypeptide comprising the other domains of the chimeric immunogen.

The procedure for attaching a *Pseudomonas* exotoxin chimera to an antibody or other cell specific ligand will vary according to the chemical structure of the toxin. Antibodies contain a variety of functional groups; *e.g.*, sulfhydryl (-S), carboxylic acid (COOH) or free amine (-NH<sub>2</sub>) groups, which are available for reaction with a suitable functional group on a toxin. Additionally, or alternatively, the antibody or *Pseudomonas* exotoxin chimera can be derivatized to expose or attach additional reactive functional groups. The derivatization may involve attachment of any of a number of linker molecules such as those available from Pierce Chemical Company, Rockford Illinois.

A bifunctional linker having one functional group reactive with a group on the *Pseudomonas* exotoxin chimera, and another group reactive with a cell specific ligand, can be used to form a desired conjugate. Alternatively, derivatization may involve chemical treatment of the *Pseudomonas* exotoxin chimera or the cell specific ligand, *e.g.*, glycol cleavage of the sugar moiety of a glycoprotein antibody with periodate to generate free aldehyde groups. The free aldehyde groups on the antibody may be reacted with free amine or hydrazine groups on the antibody to bind the *Pseudomonas* exotoxin chimera thereto. (See J.D. Rodwell et al., U.S. Patent No. 4,671,958.) Procedures for generation of free sulfhydryl groups on antibodies or other proteins, are also known. (See R.A. Nicoletti et al., U.S. Pat. No. 4,659,839.)

### C. Translocation Domain

PE-like chimeric immunogens also comprise an amino acid sequence encoding a "PE translocation domain." The PE translocation domain comprises an amino acid sequence sufficient to effect translocation of chimeric proteins that have been



endocytosed by the cell into the cytosol. The amino acid sequence is identical to, or substantially identical to, a sequence selected from domain II of PE.

5 The amino acid sequence sufficient to effect translocation can derive from the translocation domain of native PE. This domain spans amino acids 253-364. The translocation domain can include the entire sequence of domain II. However, the entire sequence is not necessary for translocation. For example, the amino acid sequence can minimally contain, e.g., amino acids 280-344 of domain II of PE. Sequences outside this region, i.e., amino acids 253-279 and/or 345-364, can be eliminated from the domain. This domain also can be engineered with substitutions so long as translocation  
10 activity is retained.

The translocation domain functions as follows. After binding to a receptor on the cell surface, the chimeric proteins enter the cell by endocytosis through clathrin-coated pits. Residues 265 and 287 are cysteines that form a disulfide loop. Once internalized into endosomes having an acidic environment, the peptide is cleaved by the  
15 protease furin between Arg279 and Gly280. Then, the disulfide bond is reduced. A mutation at Arg279 inhibits proteolytic cleavage and subsequent translocation to the cytosol. M. Ogata *et al.* (1990) *J. Biol. Chem.* 265:20678-85. However, a fragment of PE containing the sequence downstream of Arg279 (called "PE37") retains substantial ability to translocate to the cytosol. C.B. Siegall *et al.* (1989) *J. Biol. Chem.*  
20 264:14256-61. Sequences in domain II beyond amino acid 345 also can be deleted without inhibiting translocation. Furthermore, amino acids at positions 339 and 343 appear to be necessary for translocation. C.B. Siegall *et al.* (1991) *Biochemistry* 30:7154-59.

25 Methods for determining the functionality of a translocation domain are described below in the section on testing.

#### D. Non-native Epitope Domain

PE-like chimeric immunogens also comprise an amino acid sequence encoding a "non-native epitope domain." The non-native epitope domain comprises the  
30 amino acid sequence of a non-native epitope. The domain functions to contain the immunogenic non-native epitope for presentation to the immune system. The non-native epitope domain is engineered into the Ib domain location of PE, between the translocation domain (e.g., domain II) and the ER retention domain (e.g., domain III).

Methods of determining immunogenicity of a translocation domain are described below in the section on testing.

The non-native epitope can be any amino acid sequence that is immunogenic. The non-native epitope domain can have between about 5 amino acids and about 1500 amino acids. This includes domains having between about 15 amino acids and about 350 amino acids or about 15 amino acids and about 50 amino acids.

In native *Pseudomonas* exotoxin A, domain Ib spans amino acids 365 to 399. The native Ib domain is structurally characterized by a disulfide bond between two cysteines at positions 372 and 379. Domain Ib is not essential for cell binding, translocation, ER retention or ADP ribosylation activity. Therefore, it can be entirely re-engineered.

The non-native epitope domain can be linear or it can include a cysteine-cysteine loop that comprises the non-native epitope. In one embodiment, the non-native epitope domain includes a cysteine-cysteine loop that comprises the non-native epitope. This arrangement offers several advantages. First, when the non-native epitope naturally exists inside, or comprises, a cysteine-cysteine disulfide bonded loop, the non-native epitope domain will present the epitope in near-native conformation. Second, it is believed that charged amino acid residues in the native Ib domain result in a hydrophilic structure that sticks out away from the molecule and into the solvent, where it is available to interact with immune system components. Therefore, placing the non-native epitope within a cysteine-cysteine loop results in more effective presentation when the non-native epitope also is hydrophilic. Third, the Ib domain is highly insensitive to mutation. Therefore, although the cysteine-cysteine loop of the native Ib domain has only six amino acids between the cysteine residues, one can insert much longer sequences into the loop without disrupting cell binding, translocation, ER retention or ADP ribosylation activity.

This invention envisions several ways in which to engineer the non-native epitope domain into the Ib domain location. One method involves inserting the amino acid sequence of the non-native epitope directly into the amino acid sequence of the Ib domain, with or without deletion of native amino acid sequences. Another method involves removing all or part of the Ib domain and replacing it with an amino acid sequence that includes the non-native epitope between two cysteine residues so that the cysteines engage in a disulfide bond when the protein is expressed. For example, if the

non-native epitope normally exists within a cysteine-cysteine loop structure of a polypeptide, a portion of the polypeptide that includes the loop and the non-native epitope can be inserted in place of the cysteine-cysteine loop domain.

The choice of the non-native epitope is at the discretion of the practitioner.

5 In choosing, the practitioner may consider the following. While the non-native epitope domain can be linear, non-native epitopes that naturally exist within a cysteine-cysteine loop take advantage of the natural structure of the Ib loop of *Pseudomonas* exotoxin A. Epitopes from agents responsible for indolent infections or cancer-specific antigens are attractive because these antigens tend to resist attack from the immune system. Also,  
10 recombinant technology allows one to quickly insert a polynucleotide encoding an epitope into a vector encoding the chimeric protein. Therefore, one can quickly change sequences as a non-native epitope changes. Accordingly, epitopes from rapidly evolving infectious agents make attractive inserts.

Thus, for example, epitopes can be chosen from any pathogen, e.g.,  
15 viruses, bacteria and protozoan parasites. Viral sources of epitopes include, for example, HIV, herpes zoster, influenza, polio and hepatitis. Bacterial sources include, for example, tuberculosis, Chlamydia or Salmonella. Parasitic protozoan sources include, for example, *Trypanosoma* or *Plasmodium*. In particular, the agent can be one that gains entry into the body through epithelial mucosal membranes. Useful cancer-  
20 specific antigens include those that are expressed on the cell surface and, therefore, can be target of a cytotoxic T-lymphocyte response, such as a prostate cancer-specific marker (e.g., PSA), a breast cancer-specific marker (e.g., BRCA-1 or HER2), a pancreatic cancer-specific marker (e.g., CA9-19), a melanoma marker (e.g., tyrosinase) or a cancer-specific mutant form of EGF.

25 In one embodiment, the non-native epitope derives from the principal neutralizing loop of a retrovirus, such as HIV-1 or HIV-2. In particular, the epitope can derive from the V3 loop of gp120 protein from HIV-1. A neutralizing loop can be identified by neutralizing antibodies, i.e., antibodies that neutralize infectivity of the virus. The sequences can be from any strain, in particular, circulating strains. Such  
30 strains include, for example, MN (e.g., subtype B) or Thai-E (e.g., subtype E). V3 loops of various strains of HIV-1 have about 35 amino acids. The strains of HIV can be T-cell tropic or macrophage tropic. In one embodiment, the sequences from the V3 loop include at least 8 amino acids (e.g., a peptide sufficiently long to fit into an MHC Class

II binding pocket) that includes a V3 loop apex. The V3 loop of MN strain of HIV has the sequence: CTRPNYNKRK RIHIGPGRAF YTTKNIIGTI RQAHG (SEQ ID NO:3). The V3 loop of Thai-E strain of HIV has the sequence: CTRPSNNTRT SITIGPGOVF YRTGDIIGDI RKAYC (SEQ ID NO:4). The V3 loop apex is underlined. The  
5 sequence be around 14 to around 26 amino acids long. A vaccine can comprise a plurality of immunogens having different viral epitopes.

In another embodiment the non-native epitope can be an epitope expressed by a cell during disease. For example, the non-native epitope can be a cancer cell marker. For example, certain breast cancers express a mutant EGF ("epidermal growth  
10 factor") receptor that results from a splice variant. This mutant form exhibits a unique epitope.

#### E. ER Retention Domain

PE-like chimeric immunogens also can comprise an amino acid sequence  
15 encoding an "endoplasmic reticulum retention domain." The endoplasmic reticulum ("ER") retention domain functions in translocating the chimeric protein to from the endosome to the endoplasmic reticulum, from where it is transported to the cytosol. The ER retention domain is located at the position of domain III in PE. The ER retention domain comprises an amino acid sequence that has, at its carboxy terminus, an ER  
20 retention sequence. The ER retention sequence in native PE is REDLK (SEQ ID NO:11). Lysine can be eliminated (i.e., REDL (SEQ ID NO:12)) without a decrease in activity. REDLK (from SEQ ID NO:1) can be replaced with other ER retention sequences, such as KDEL (SEQ ID NO:12), or polymers of these sequences. M. Ogata  
25 *et al.* (1990) *J. Biol. Chem.* 265:20678-85. Pastan *et al.*, U.S. Patent 5,458,878. I. Pastan *et al.* (1992) *Annu. Rev. Biochem.* 61:331-54.

Sequences up-stream of the ER retention sequence can be the native PE domain III (preferably de-toxified), can be entirely eliminated, or can be replaced by another amino acid sequence. If replaced by another amino acid sequence, the sequence  
30 can, itself, be highly immunogenic or can be slightly immunogenic. A highly immunogenic ER retention domain is preferable for use in eliciting a humoral immune response. Chimeras in which the ER retention domain is only slightly immunogenic will be more useful when an MHC Class I-dependent cell-mediated immune response is desired.

Activity of this domain can be assessed by testing for translocation of the protein into the target cell cytosol using the assays described below.

In native PE, the ER retention sequence is located at the carboxy terminus of domain III. Domain III has two functions in PE. It exhibits ADP-ribosylating activity and directs endocytosed toxin into the endoplasmic reticulum. Eliminating the ER retention sequence from the chimeric protein does not alter the activity of *Pseudomonas* exotoxin as a superantigen, but does inhibit its utility to elicit an MHC Class I-dependent cell-mediated immune response.

The ribosylating activity of PE is located between about amino acids 400 and 600 of PE. In methods of vaccinating a subject using the chimeric proteins of this invention, it is preferable that the protein be non-toxic. One method of doing so is by eliminating ADP ribosylation activity. In this way, the chimeric protein can function as a vector for non-native epitope sequences to be processed by the cell and presented on the cell surface with MHC Class I molecules, rather than as a toxin. ADP ribosylation activity can be eliminated by, for example, deleting amino acid E553 ("ΔE553"). M. Lukac *et al.* (1988) *Infect. and Immun.* 56:3095-3098. Alternatively, the amino acid sequence of domain III, or portions of it, can be deleted from the protein. Of course, an ER retention sequence should be included at the carboxy-terminus.

In one embodiment, the sequence of the ER retention domain is substantially identical to the native amino acid sequences of the domain III, or a fragment of it. In one embodiment, the ER retention domain is domain III of PE.

In another embodiment, a cell recognition domain is inserted into the amino acid sequence of the ER retention domain (e.g., into domain III). For example, the cell recognition domain can be inserted just up-stream of the ER retention sequence, so that the ER retention sequence is connected directly or within ten amino acids of the carboxy terminus of the cell recognition domain.

#### F. Methods Of Making PE-like Chimeric Immunogens

PE-like chimeric immunogens preferably are produced recombinantly, as described below. This invention also envisions the production of PE chimeric proteins by chemical synthesis using methods available to the art.

#### G. Testing PE-like Immunogenic Chimeras

Having selected various structures as domains of the chimeric immunogen, the function of these domains, and of the chimera as a whole, can be tested to detect functionality. PE-like immunogenic chimeras can be tested for cell recognition, cytosolic translocation and immunogenicity using routine assays. The entire chimeric protein can be tested, or, the function of various domains can be tested by substituting them for native domains of the wild-type toxin.

**1. Receptor binding/Cell recognition**

The function of the cell binding domain can be tested as a function of the chimera to bind to the target receptor either isolated or on the cell surface.

In one method, binding of the chimera to a target is performed by affinity chromatography. For example, the chimera can be attached to a matrix in an affinity column, and binding of the receptor to the matrix detected.

Binding of the chimera to receptors on cells can be tested by, for example, labeling the chimera and detecting its binding to cells by, e.g., fluorescent cell sorting, autoradiography, etc.

If antibodies have been identified that bind to the ligand from which the cell recognition domain is derived, they also are useful to detect the existence of the cell recognition domain in the chimeric immunogen by immunoassay, or by competition assay for the cognate receptor.

**2. Translocation to the cytosol**

The function of the translocation domain and the ER retention domain can be tested as a function of the chimera's ability to gain access to the cytosol. Because access first requires binding to the cell, these assays also are useful to determine whether the cell recognition domain is functioning.

**a. Presence in the cytosol**

In one method, access to the cytosol is determined by detecting the physical presence of the chimera in the cytosol. For example, the chimera can be labelled and the chimera exposed to the cell. Then, the cytosolic fraction is isolated and the amount of label in the fraction determined. Detecting label in the fraction indicates that the chimera has gained access to the cytosol.

**b. ADP Ribosylation activity**

In another method, the ability of the translocation domain and ER retention domain to effect translocation to the cytosol can be tested with a construct containing a

domain III having ADP ribosylation activity. Briefly, cells are seeded in tissue culture plates and exposed to the chimeric protein or to an engineered PE exotoxin containing the modified translocation domain or ER retention sequence in place of the native domains. ADP ribosylation activity is determined as a function of inhibition of protein synthesis by, e.g., monitoring the incorporation of <sup>3</sup>H-leucine.

### 3. Immunogenicity

The function of the non-native epitope can be determined by determining humoral or cell-mediated immunogenicity. Immunogenicity can be tested by several methods. Humoral immune response can be tested by inoculating an animal and detecting the production of antibodies against the foreign immunogen. Cell-mediated cytotoxic immune responses can be tested by immunizing an animal with the immunogen, isolating cytotoxic T cells, and detecting their ability to kill cells whose MHC Class I molecules bear amino acid sequences from the non-native epitope. Because generating a cytotoxic T cell response requires both binding of the chimera to the cell and translocation to the cytosol, this test also tests the activity of the cell recognition domain, the translocation domain and the ER retention domain.

## III. RECOMBINANT POLYNUCLEOTIDES ENCODING PE-LIKE CHIMERIC IMMUNOGENS

### A. Recombinant Polynucleotides

#### 1. Sources

This invention provides recombinant polynucleotides comprising a nucleotide sequence encoding the PE-like chimeric immunogens of this invention. These polynucleotides are useful for making the PE-like chimeric immunogens. In another aspect, this invention provides a PE-like protein cloning platform comprising a recombinant polynucleotide sequence encoding a cell recognition domain, a translocation domain, an ER retention domain and, between the translocation domain and the ER retention domain, a cloning site for a polynucleotide sequence encoding a non-native epitope domain.

The recombinant polynucleotides of this invention are based on polynucleotides encoding *Pseudomonas* exotoxin A, or portions of it. A nucleotide sequence encoding PE is presented above. The practitioner can use this sequence to

prepare PCR primers for isolating a full-length sequence. The sequence of PE can be modified to engineer a polynucleotide encoding the PE-like chimeric immunogen or platform.

5 A polynucleotide encoding PE or any other polynucleotide used in the chimeric proteins of the invention can be cloned or amplified by *in vitro* methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the self-sustained sequence replication system (3SR) and the Q $\beta$  replicase amplification system (QB). For example, a  
10 polynucleotide encoding the protein can be isolated by polymerase chain reaction of cDNA using primers based on the DNA sequence of PE or a cell recognition molecule.

A wide variety of cloning and *in vitro* amplification methodologies are well-known to persons skilled in the art. PCR methods are described in, for example, U.S. Pat. No. 4,683,195; Mullis *et al.* (1987) *Cold Spring Harbor Symp. Quant. Biol.* 51:263; and Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989). Polynucleotides  
15 also can be isolated by screening genomic or cDNA libraries with probes selected from the sequences of the desired polynucleotide under stringent hybridization conditions.



## 2. Mutagenized versions

5 Mutant versions of the proteins can be made by site-specific mutagenesis of other polynucleotides encoding the proteins, or by random mutagenesis caused by increasing the error rate of PCR of the original polynucleotide with 0.1 mM MnCl<sub>2</sub> and unbalanced nucleotide concentrations.

10 Eliminating nucleotides encoding amino acids 1-252 yields a construct referred to as "PE40." Eliminating nucleotides encoding amino acids 1-279 yields a construct referred to as "PE37." (See Pastan *et al.*, U.S. patent 5,602,095.) The practitioner can ligate sequences encoding cell recognition domains to the 5' end of these platforms to engineer PE-like chimeric proteins that are directed to particular cell surface receptors. These constructs optionally can encode an amino-terminal methionine. A cell recognition domain can be inserted into such constructs in the nucleotide sequence encoding the ER retention domain.

## 3. Chimeric protein cloning platforms

15 A cloning site for the non-native epitope domain can be introduced between the nucleotides encoding the cysteine residues of domain Ib. For example, as described in the Examples, a nucleotide sequence encoding a portion of the Ib domain between the cysteine-encoding residues can be removed and replaced with a nucleotide sequence encoding an amino acid sequence and that includes a PstI cloning site. A polynucleotide encoding the non-native epitope and flanked by PstI sequences can be inserted into the vector.

20 The construct also can be engineered to encode a secretory sequence at the amino terminus of the protein. Such constructs are useful for producing the immunogens in mammalian cells. *In vitro*, such constructs simplify isolation of the immunogen. *In vivo*, the constructs are useful as polynucleotide vaccines; cells that incorporate the construct will express the protein and secrete it where it can interact with the immune system.

## B. Expression Vectors

30 This invention also provides expression vectors for expressing PE-like chimeric immunogens. Expression vectors are recombinant polynucleotide molecules comprising expression control sequences operatively linked to a nucleotide sequence encoding a polypeptide. Expression vectors can be adapted for function in prokaryotes

or eukaryotes by inclusion of appropriate promoters, replication sequences, markers, etc. for transcription and translation of mRNA. The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. Sambrook *et al.*, *Molecular Cloning -- A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc.) Useful promoters for such purposes include a metallothionein promoter, a constitutive adenovirus major late promoter, a dexamethasone-inducible MMTV promoter, a SV40 promoter, a MRP polIII promoter, a constitutive MPSV promoter, a tetracycline-inducible CMV promoter (such as the human immediate-early CMV promoter), and a constitutive CMV promoter. A plasmid useful for gene therapy can comprise other functional elements, such as selectable markers, identification regions, and other genes.

Expression vectors useful in this invention depend on their intended use. Such expression vectors must, of course, contain expression and replication signals compatible with the host cell. Expression vectors useful for expressing PE-like chimeric immunogens include viral vectors such as retroviruses, adenoviruses and adeno-associated viruses, plasmid vectors, cosmids, and the like. Viral and plasmid vectors are preferred for transfecting mammalian cells. The expression vector pcDNA1 (Invitrogen, San Diego, CA), in which the expression control sequence comprises the CMV promoter, provides good rates of transfection and expression. Adeno-associated viral vectors are useful in the gene therapy methods of this invention.

A variety of means are available for delivering polynucleotides to cells including, for example, direct uptake of the molecule by a cell from solution, facilitated uptake through lipofection (e.g., liposomes or immunoliposomes), particle-mediated transfection, and intracellular expression from an expression cassette having an expression control sequence operably linked to a nucleotide sequence that encodes the inhibitory polynucleotide. See also Inouye *et al.*, U.S. Patent 5,272,065; *Methods in Enzymology*, vol. 185, Academic Press, Inc., San Diego, CA (D.V. Goeddel, ed.) (1990) or M. Krieger, *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, New York, NY, (1990). Recombinant DNA expression plasmids can also be used to prepare the polynucleotides of the invention for delivery by means other than by gene

therapy, although it may be more economical to make short oligonucleotides by *in vitro* chemical synthesis.

The construct can also contain a tag to simplify isolation of the protein. For example, a polyhistidine tag of, e.g., six histidine residues, can be incorporated at the amino terminal end of the protein. The polyhistidine tag allows convenient isolation of the protein in a single step by nickel-chelate chromatography.

### C. Recombinant Cells

The invention also provides recombinant cells comprising an expression vector for expression of the nucleotide sequences encoding a PE chimeric immunogen of this invention. Host cells can be selected for high levels of expression in order to purify the protein. The cells can be prokaryotic cells, such as *E. coli*, or eukaryotic cells. Useful eukaryotic cells include yeast and mammalian cells. The cell can be, e.g., a recombinant cell in culture or a cell *in vivo*.

*E. coli* has been successfully used to produce PE-like chimeric immunogens. The protein can fold and disulfide bonds can form in this cell.

## IV. PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGEN VACCINES

PE-like chimeric immunogens are useful in vaccines for eliciting a protective immune response against agents bearing the non-native epitope. A vaccine can include one or a plurality (i.e. a multivalent vaccine) of different PE-like chimeric immunogens. For example, a vaccine can include PE-like chimeric immunogens whose non-native epitopes come from several circulating strains of a pathogen. As the pathogen evolves, new PE-like chimeric immunogens can be constructed that include the altered epitopes, for example, from breakthrough viruses. In one embodiment, the vaccine comprises epitopes from a T-cell-tropic virus and from a macrophage-tropic virus. For example, a vaccine against HIV infection can include immunogens whose non-native epitopes derive from the V3 loop of MN and Thai-E strains of HIV. Also, the epitopes can derive from any peptide from HIV that is involved in membrane fusion, e.g., gp120 or gp41. Alternatively, because they are subunit vaccines, the vaccine can include PE-like chimeric immunogens whose non-native epitopes are selected from various epitopes of the same pathogen.

The vaccine can come lyophilized or already reconstituted in sterile solution for use. An immunizing dose is between about 1  $\mu$ g and about 1000  $\mu$ g, more usually between about 10  $\mu$ g and about 50  $\mu$ g of the recombinant protein. For determination of immunizing doses see, for example, *Manual of Clinical Immunology*, H.R. Rose and H. Friedman, American Society for Microbiology, Washington, D.C. (1980). A unit dose is about 0.05 ml to about 1 ml, more usually about 0.5 ml. A dose is preferably delivered subcutaneously or intramuscularly. An injection can be followed by several more injections spaced about 4 to about 8 weeks apart. Booster doses can follow in about 1 to about 10 years. The vaccine can be prepared in dosage forms containing between 1 and 50 doses (e.g., 0.5 ml to 25 ml), more usually between 1 and 10 doses (e.g., 0.5 ml to 5 ml). The vaccine also can include an adjuvant, that potentiates an immune response when used in conjunction with an antigen. Useful adjuvants include alum, aluminum hydroxide or aluminum phosphate.

## V. METHODS OF ELICITING AN IMMUNE RESPONSE

PE-like chimeric immunogens are useful in eliciting an immune response against antigens bearing the non-native epitope. Eliciting a humoral immune response is useful in the production of antibodies that specifically recognize the non-native epitope and in immunization against cells, viruses or other agents that bear the non-native epitope. PE-like chimeric immunogens are also useful in eliciting MHC Class I-dependent or MHC Class II-dependent cell-mediated immune responses. They are also useful in eliciting a secretory immune response.

### A. Prophylactic and Therapeutic Treatments

PE-like chimeric immunogens can include non-native epitopes from pathogenic organisms or from pathological cells from a subject, such as cancer cells. Accordingly, this invention provides prophylactic and therapeutic treatments for diseases involving the pathological activity of agents, either pathogens or aberrant cells, that bear the non-native epitope. The methods involve immunizing a subject with PE-like chimeric immunogens bearing the non-native epitope. The resulting immune responses mount an attack against the pathogens, themselves, or against cells that express the non-native epitope. For example, if the pathology results from bacterial or parasitic protozoan infection, the immune system mounts a response against the pathogens, themselves. If

the pathogen is a virus, infected cells will express the non-native epitope on their surface and become the target of a cytotoxic response. Aberrant cells, such as cancer cells, often express un-normal epitopes, and also can be subject to a cytotoxic immune response.

5

#### B. Humoral Immune Response

PE-like chimeric immunogens are useful in eliciting the production of antibodies against the non-native epitope by a subject. PE-like chimeric immunogens are attractive immunogens for making antibodies against non-native epitopes that naturally occur within a cysteine-cysteine loop: Because they contain the non-native epitope within a cysteine-cysteine loop, they present the epitope to the immune system in near-native conformation. The resulting antibodies generally recognize the native antigen better than those raised against linearized versions of the non-native epitope.

Methods for producing polyclonal antibodies are known to those of skill in the art. In brief, an immunogen, preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (e.g., GST, keyhole limpet hemanocyanin, etc.), or a polypeptide incorporated into an immunization vector, such as a recombinant vaccinia virus (see, U.S. Patent No. 4,722,848) is mixed with an adjuvant. Animals are immunized with the mixture. An animal's immune response to the immunogenic preparation is monitored by taking test bleeds and determining the titer of reactivity to the polypeptide of interest. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the polypeptide is performed where desired. See, e.g., Coligan (1991) *Current Protocols in Immunology* Wiley/Greene, NY; and Harlow and Lane (1989) *Antibodies: A Laboratory Manual* Cold Spring Harbor Press, NY.

In various embodiments, the antibodies ultimately produced can be monoclonal antibodies, humanized antibodies, chimeric antibodies or antibody fragments.

Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies are screened for binding to polypeptides comprising the epitope, or screened for agonistic or antagonistic activity, e.g., activity mediated through the agent comprising the non-native epitope. In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates,

30

humans, etc. Description of techniques for preparing such monoclonal antibodies are found in, e.g., Stites *et al.* (eds.) *Basic and Clinical Immunology* (4th ed.) Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane, *Supra*; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.) Academic Press, New York, NY; and Kohler and Milstein (1975) *Nature* 256: 495-497.

In another embodiment, the antibodies are humanized immunoglobulins. Humanized antibodies are made by linking the CDR regions of non-human antibodies to human constant regions by recombinant DNA techniques. See Queen *et al.*, United States patent 5,585,089.

In another embodiment of the invention, fragments of antibodies against the non-native epitope are provided. Typically, these fragments exhibit specific binding to the non-native epitope similar to that of a complete immunoglobulin. Antibody fragments include separate heavy chains, light chains, Fab, Fab' F(ab')<sub>2</sub> and Fv. Fragments are produced by recombinant DNA techniques, or by enzymic or chemical separation of intact immunoglobulins.

Other suitable techniques involve selection of libraries of recombinant antibodies in phage or similar vectors. See, Huse *et al.* (1989) *Science* 246: 1275-1281; and Ward *et al.* (1989) *Nature* 341: 544-546.

An approach for isolating DNA sequences which encode a human monoclonal antibody or a binding fragment thereof is by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science* 246:1275-1281 (1989) and then cloning and amplifying the sequences which encode the antibody (or binding fragment) of the desired specificity. The protocol described by Huse is rendered more efficient in combination with phage display technology. See, e.g., Dower *et al.*, WO 91/17271 and McCafferty *et al.*, WO 92/01047. Phage display technology can also be used to mutagenize CDR regions of antibodies previously shown to have affinity for the polypeptides of this invention or their ligands. Antibodies having improved binding affinity are selected.

The antibodies of this invention are useful for affinity chromatography in isolating agents bearing the non-native epitope. Columns are prepared, e.g., with the antibodies linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate is passed through the column, washed, and treated with increasing concentrations of a mild denaturant, whereby purified agents are released.

Antibodies were produced against gp120 using a PE-like chimeric immunogen having the gp120 V3 loop as the non-native epitope. The monoclonal antibodies selectively captured the soluble MN and Th-E chimeric proteins, confirming that the V3 loops were exposed and accessible to antibody probes. Also, sera from immunized rabbits neutralized HIV-1 infectivity in an *in vitro* assay.

#### C. MHC Class II-dependent Cell-mediated Immune Response

In another aspect, this invention provides methods for eliciting an MHC Class II-dependent immune response against cells expressing the non-native epitope. MHC Class II molecules bind peptides having particular amino acid motifs well known in the art. The MHC Class II-dependent response involves the uptake of an antigen by antigen-presenting cells (APC's), its processing, and presentation on the cell surface as part of an MHC Class II/antigenic peptide complex. Alternatively, MHC Class II molecules on the cell surface can bind peptides having the proper motif.

Antigen presenting cells interact with CD4-positive T-helper cells, thereby activating the T-helper cells. Activated T-helper cells stimulate B-lymphocytes to produce antibodies against the antigen. Antibodies mark cells bearing the antigen on their surface. The marked cells are subject to antibody-dependent cell-mediated cytotoxicity, in which NK cells or macrophages, which bear Fc receptors, attack the marked cells.

Methods for eliciting an MHC Class II-dependent immune response involve administering to a subject a vaccine including an immunogenic amount of a chimeric *Pseudomonas* exotoxin that includes an amino acid motif recognized by MHC Class II molecules of the subject. Alternatively, antigen presenting cells can be cultured with such peptides to allow binding, and the cells can be administered to the subject. Preferably, the cells are syngeneic with the subject.

#### D. MHC Class I-dependent Cell-mediated Immune Response

In another aspect, this invention provides methods for eliciting an MHC Class I-dependent cell-mediated immune response against cells expressing the non-native epitope in a subject. MHC Class I molecules bind peptides having particular amino acid motifs well known in the art. Proteins expressed in a cell are digested into peptides and presented on the cell surface in association with MHC Class I molecules. There, they

are recognized by CD8-positive lymphocytes, generating a cytotoxic T-lymphocyte response against cells expressing the epitopes in association with MHC Class I molecules. Because CD4-positive T lymphocytes infected with HIV express gp120 and, thus, the V3 domain, the generation of cytotoxic T-lymphocytes that attack such cells is useful in the prophylactic or therapeutic treatment of HIV infections.

HLA-A1 binding motif includes a first conserved residue of T, S or M, a second conserved residue of D or E, and a third conserved residue of Y. Other second conserved residues are A, S or T. The first and second conserved residues are adjacent and are preferably separated from the third conserved residue by 6 to 7 residues. A second motif consists of a first conserved residue of E or D and a second conserved residue of Y where the first and second conserved residues are separated by 5 to 6 residues. The HLA-A3.2 binding motif includes a first conserved residue of L, M, I, V, S, A, T and F at position 2 and a second conserved residue of K, R or Y at the C-terminal end. Other first conserved residues are C, G or D and alternatively E. Other second conserved residues are H or F. The first and second conserved residues are preferably separated by 6 to 7 residues. The HLA-A11 binding motif includes a first conserved residue of T or V at position 2 and a C-terminal conserved residue of K. The first and second conserved residues are preferably separated by 6 or 7 residues. The HLA-A24.1 binding motif includes a first conserved residue of Y, F or W at position 2 and a C terminal conserved residue of F, I, W, M or L. The first and second conserved residues are preferably separated by 6 to 7 residues.

Another method involves transfecting cells *ex vivo* with such expression vectors, and administering the cells to the subject. The cells preferably are syngeneic to the subject.

Methods for eliciting an immune response against a virus in a subject are useful in prophylactic methods for preventing infection with the virus when the vaccine is administered to a subject who is not already infected.

#### E. IgA-mediated Secretory Immune Response

Mucosal membranes are primary entryways for many infectious pathogens. Such pathogens include, for example, HIV, herpes, vaccinia, cytomegalovirus, yersinia and vibrio. Mucosal membranes include the mouth, nose, throat, lung, vagina, rectum and colon. As a defense against entry, the body secretes secretory IgA on the surfaces



of mucosal epithelial membranes against pathogens. Furthermore, antigens presented at one mucosal surface can trigger responses at other mucosal surfaces due to trafficking of antibody-secreting cells between these mucosae. The structure of secretory IgA has been suggested to be crucial for its sustained residence and effective function at the luminal surface of a mucosa. As used herein, "secretory IgA" or "sIgA" refers to a polymeric molecule comprising two IgA immunoglobulins joined by a J chain and further bound to a secretory component. While mucosal administration of antigens can generate an IgG response, parenteral administration of immunogens rarely produce strong sIgA responses. Generating a secretory immune response for defense against HIV is a recognized need. (Bukawa, H., *et al.* 1995, *Nat Med* 1, 681-5; Mestecky, J., *et. al.*, 1994, *Aids Res Hum Retroviruses* 10, S11-20.)

*Pseudomonas* exotoxin binds to receptors on mucosal membranes. Therefore, PE-like chimeric immunogens are an attractive vector for bringing non-native epitopes to a mucosal surface. There, the immunogens elicit an IgA-mediated immune response against the immunogen. Accordingly, this invention provides PE-like chimeric immunogens comprising a non-native epitope from a pathogen that gains entry through mucosal membranes. The cell recognition domain can be targeted to any mucosal surface receptor. These PE-like chimeric immunogens are useful for eliciting an IgA-mediated secretory immune response against immunogens that gain entry to the body through mucosal surfaces. PE-like chimeric immunogens used for this purpose should have ligands that bind to receptors on mucosal membranes as their cell recognition domains. For example, epidermal growth factor binds to the epidermal growth factor receptor on mucosal surfaces.

The immunogens can be applied to the mucosal surface by any of the typical means, including pharmaceutical compositions in the form of liquids or solids, e.g., sprays, ointments, suppositories or erodible polymers impregnated with the immunogen. Administration can involve applying the immunogen to a plurality of different mucosal surfaces in a series of immunizations, e.g., as booster immunizations. A booster inoculation also can be administered parenterally, e.g., subcutaneously. The immunogen can be administered in doses of about 1  $\mu\text{g}$  to 1000  $\mu\text{g}$ , e.g., about 10  $\mu\text{g}$  to 100  $\mu\text{g}$ .

Subcutaneous inoculation with vaccines comprising an epitope from the principal neutralizing domain of gp120 of HIV is not known to generate secretory IgA.

Accordingly, mucosal presentation of the chimeric immunogens of this invention is useful for producing these hitherto unknown antibodies. This invention also provides secretory IgA that specifically recognize epitopes of other pathogens that enter the body through a mucous membrane.

5                   The IgA response is strongest on mucosal surfaces exposed to the immunogen. Therefore, in one embodiment, the immunogen is applied to a mucosal surface that is likely to be a site of exposure to the particular pathogen. Accordingly, chimeric immunogens against sexually transmitted diseases can be administered to vaginal, anal or oral mucosal surfaces.

10                   Mucosal administration of the chimeric immunogens of this invention result in strong memory responses, both for IgA and IgG. Therefore, in vaccination with them, it is useful to provide booster doses either mucosally or parenterally. The memory response can be elicited by administering a booster dose more than a year after the initial dose. For example, a booster dose can be administered about 12, about 16,  
15                   about 20 or about 24 months after the initial dose.

## VI. POLYNUCLEOTIDE VACCINES AND METHODS OF GENE THERAPY

Vaccines comprising polynucleotides encoding a protein immunogen, often called "DNA vaccines," offer certain advantages over polypeptide vaccines. DNA  
20                   vaccines do not run the risk of contamination with unwanted protein immunogens. Upon administration to a subject, the polynucleotide is taken up by a cell. RNA is reverse transcribed into DNA. DNA is integrated into the genome in some percentage of transfected cells. Where the DNA integrates so as to be operatively linked with expression control sequences, or if such sequences are provided with the recombinant  
25                   polynucleotide, the cell expresses the encoded polypeptide. Upon secretion from the cell, the polypeptide acts as an immunogen. Naked DNA is preferentially taken up by liver and by muscle cells. Accordingly, the polypeptide can be injected into muscle tissue, or provided by, e.g., biolistic injection. Generally, doses of naked polynucleotide will be from about 1  $\mu$ g to 100  $\mu$ g for a typical 70 kg patient.

30                   The polynucleotide vaccines of this invention can include polynucleotides encoding PE-like chimeric immunogens that are used in polypeptide vaccines. This includes multiple immunogens including several variants of an epitope.

The following examples are offered by way of illustration, not by way of limitation.

## EXAMPLES

### 5 I. CONSTRUCTION OF PE-LIKE CHIMERIC IMMUNOGENS

To generate chimeric proteins, the subdomain Ib of ntPE was replaced with V3 loop sequences from either an MN (subtype B) or Thai-E subtype strain of HIV-1. The MN sequence is from a T-cell-tropic strain while the Thai-E sequence comes from a macrophage-tropic strain.

10 Wild-type (WT) PE is composed of 613 amino acids and has a molecular mass of 67,122 Da. Deletion of a glutamic acid 553 ( $\Delta E553$ ) results in a non-toxic version of PE (Lukac, M., *et al.*, 1988, *Infect and Immun* 56:3095-3098), referred to as ntPE.

Plasmids were constructed by inserting oligonucleotide duplexes encoding  
15 V3 loop sequences into a new PE-based vector that was designed with a novel PstI site. In an effort to produce a V3 loop of similar topology to that found in gp120, the 14 or 26 amino acid inserts were flanked by cysteine residues (Fig. 1C - bold type). Construction of the novel vector resulted in several changes in the amino acid sequence of ntPE near the insertion point of the V3 loop (Fig. 1C - italics). The non-toxic  
20 chimeras, ntPE-V3MN14, ntPE-V3MN26 and ntPE-V3Th-E26, contained V3 loops of 14 or 26 amino acids from the MN strain or 26 amino acids from the Thai-E strain, respectively (nt = "non-toxic"). Insertion of an irrelevant 16 amino acid sequence resulted in the construction of a control chimera referred to as ntPE-fp126. Removal of the Ib loop (6 amino acids) and modification of flanking amino acids adjacent to the V3  
25 loop insert resulted in a small increase in molecular mass compared to wild-type PE (Fig. 1C).

More specifically, plasmid pMOA1A2VK352 (Ogata, M., *et al.*, 1992, *J Biol Chem*, 267, 25396-401), encoding PE, was digested with SfiI and ApaI (residues 1143 and 1275, respectively) and then re-ligated with a duplex containing a novel PstI  
30 site. The coding strand of the duplex had the following sequence: 5'-tgccctgac cctggccgcc gccgagagcg agcgcttcgt ccggcagggc accggcaacg acgaggccgg cgcggaac ctcagggcc -3' (SEQ ID NO:5). The resulting plasmid encoded a slightly smaller version of PE and lacked much of domain Ib. The PstI site was then used to introduce

duplexes encoding V3 loop sequences flanked by cysteine residues. To make non-toxic proteins, vectors were modified by the subcloning in an enzymatically inactive domain III from pVC45ΔE553. An additional subcloning, from pJH4 (Hwang, J., *et. al.*, 1987, *Cell*, 48, 129-136), was needed to produce a vector that lacked a signal sequence.

5 Insertion of duplexes and subcloning modifications were initially verified by restriction analysis while final constructs were confirmed by dideoxy double strand sequencing.

## II. CHARACTERIZATION OF CHIMERAS

### A. Expression

10 All ntPE-V3 loop chimeric proteins were expressed in *E. coli* SA2821/BL21(λDE3) using a T7 promoter/T7 polymerase system (Studier, F.W., *et. al.*, 1990, *Methods Enzymol* 185, 60-89). SA2821/BL21(λDE3) cells were transformed with the appropriate plasmid and grown to an absorbance of 1.0 (600 nm) in medium containing ampicillin. To induce high level protein expression, isopropyl-β-D-  
15 thiogalactoside (1 mM) was added to the culture and incubated for an additional 90 min. *E. coli* cell pellets, were resuspended in 50 mM Tris/20 mM EDTA, pH 8.0 (TE buffer) and dispersed using a Tissue Miser. Cell lysis was accomplished with lysozyme (200 μg/ml final concentration; Sigma) and membrane associated proteins were solubilized by the addition of 2.5% Triton X-100 and 0.5 M NaCl.

20 PE-V3 loop chimeras were present in inclusion bodies, which were recovered by centrifugation. After washing with TE containing 0.5% Triton X-100 and then with TE alone, inclusion bodies were solubilized by the addition of 6 M guanidine and 65 mM dithioerythritol. Refolding was allowed to proceed at a final protein concentration of 100 μg/ml for a minimum of 24 h at 8°C in 0.1 M Tris (pH 8.0)  
25 containing 0.5 M L-arginine (Sigma), 2 mM EDTA and 0.9 mM glutathione. The protease inhibitor AEBSF (Boehringer Mannheim) was added to a final concentration of 0.5 mM. Proteins were dialyzed against 20 mM Tris, 2 mM EDTA and 100 mM urea, pH 7.4. Following dialysis, proteins were applied to a Q sepharose column (Pharmacia Biotech; Piscataway, NJ). After washing with 20 mM Tris (pH 8-0) containing 0.1 M  
30 NaCl, chimeric proteins were eluted with 0.3 M NaCl in the same buffer and concentrated using Centriprep-30 ultrafiltration devices (Amicon, Inc.; Beverly, MA). An HPLC gel filtration column (G3000SW from Toso Haas; Montgomeryville, PA) was

used to isolate final products. A typical yield of properly folded protein per 4L bacterial culture was 50-100 mg with a purity greater than 95%.

#### B. Biochemical Characterization

5 Chimeric proteins were separated by SDS-PAGE using 8-16% gradient polyacrylamide gels (Novex; San Diego, CA), and visualized by staining with Coomassie Blue. For Western blot analysis, proteins were transferred onto Immobilon-P membranes (Millipore Corp., Bedford, MA) and exposed to either an anti-PE mouse monoclonal antibody (M40-1 (Ogata, M., *et. al.*, 1991, *Infect and Immun* 59, 407-414) or an  
10 anti-gp120 mouse monoclonal antibody (1F12 for MN sequences or 1B2 for Thai-E sequences; Genentech, Inc.; South San Francisco, CA). The primary antibody was detected by a secondary anti-mouse antibody conjugated to horseradish peroxidase. Reactive products were visualized by the addition of diaminobenzadine and hydrogen peroxide. Immunocapture experiments were performed for 30 min at 23°C using the  
15 1F12 anti-gp120 monoclonal antibody. Antibody-chimeric protein complexes were recovered with protein G sepharose beads (Pharmacia Biotech; Piscataway, NJ) and separated using SDS-PAGE (as above). Recombinant forms of gp120 derived from HIV-1-MN (120/MN; Genentech, Inc.) and the Thai subtype E isolate (gp120/Th-E - Chiang Mai; Advanced Biotechnologies, Columbia MD) were used as standards.

20 SDS-PAGE analysis of purified ntPE-V3 loop chimeras (Fig. 2A) was consistent with calculated masses (Fig. 1C). Western blots, using monoclonal antibodies raised against gp120/MN (1F12) or gp120/Th-E (1B2), showed strain-specific reactivity with the MN and Thai-E V3 loop chimeras (Fig. 2B).

25 Free sulfhydryl analysis of purified ntPE-V3 loop chimeras failed to demonstrate any unpaired cysteines, suggesting that the purified ntPE-V3 loop chimeras had refolded and oxidized to form a disulfide bond at the base of the V3 loop (Fig. 1A). The formation of this disulfide bond was expected to result in the exposure of the V3 loop at the surface of the chimeras.

30 To determine sulfhydryl content, chimeric proteins (15 nmols) in PBS (pH 7.4) containing 1 mM EDTA, were reacted with 1 mM thionitrobenzoate (DTNB) (Pierce Chem Co, Rockford, IL) for 15 min at 23°C. The release of thionitrobenzoate was monitored at 412 nm. DTNB reactivity was confirmed by the use of cysteine.

This was tested directly by immuno-capture studies (Fig. 2C). The 1F12 and 1B2 monoclonal antibodies selectively captured the soluble MN and Th-E chimeric proteins confirming that the V3 loops were exposed and accessible to antibody probes. Despite the fact that the 1F12 antibody reacted strongly with ntPE-V3MN14 in Western blots (Fig 2B), it captured only a small amount of soluble protein (Fig. 2C, Lane 3), suggesting that the reactive epitope was not completely exposed when only 14 amino acids were inserted.

### C. Circular Dichroism

To evaluate the impact of amino acid inserts on the secondary structure of the chimeras, near- and far-UV CD spectral analysis was performed on purified ntPE-V3MN14 and ntPE-V3MN26 proteins and compared these to wild-type PE (wtPE) spectra (Figs. 3A and 3B). Circular dichroism (CD) spectra were collected on an Aviv 60DS spectropolarimeter. Near UV CD spectra (400 nm to 250 nm) were obtained in 0.2 nm increments with a 0.5 nm bandwidth and a 5 second time constant (150 readings/second averaged) for samples in a 1 cm pathlength cell. Far UV spectra (250 nm to 190 nm) were collected in 0.2 nm increments with a 0.5 nm bandwidth and a 3 second time constant in a 0.05 cm pathlength cell. Each spectrum was digitally smoothed using the Savitsky-Golay algorithm (Gorry, P.A. 1990, *Analytical Chem* 62, 570-573), corrected for concentration, and normalized to units of mean residue weight ellipticity ( $\Theta_{MRW}$ ) using the following relationship:

$$\theta_{MRW} = \frac{\theta_{obs} (MW_{monomer} / n_{monomer})}{10 (d) (c)}$$

where  $\Theta_{obs}$  is the observed ellipticity,  $MW_{monomer}$  is the molecular weight of the monomer,  $n_{monomer}$  is the number of amino acids in the monomer,  $d$  is the pathlength of the cell (cm), and  $c$  is the concentration of the sample in the cell (mg/ml).

Secondary structure calculations (Fig. 3C) suggested that there were no significant differences between these proteins and wtPE. ntPE-V3MN14 demonstrated more negative ellipticity than ntPE-V3MN26 and wtPE, suggesting more strain may occur on the disulfide bond at the base of the loop insert for this chimera. Both ntPE-V3MN14 and ntPE-V3MN26 showed an apparent red-shift at 290 nm, possibly due to the additional tyrosine residues in the chimeras. Alternately, this red-shift could result

from a slight environmental perturbation of a tryptophan residue. Altogether, these results suggest that the V3 loop inserts did not produce large alterations in the secondary structure relative to wild-type toxin and that the changes in tertiary structure were consistent with the presence of the 14 and 26 amino acid inserts.

### III. TRANSLOCATION TO THE CYTOSOL

After binding to the LRP receptor, ntPE-V3 loop chimeras should be endocytosed, cleaved by furin and the C-terminal portion containing domains II, the V3 loop and III should be translocated to the cytosol in a similar fashion to wtPE (Ogata, M., *et. al.*, 1990, *Biol Chem* 265, 20678-85). This was tested directly by producing enzymatically active versions of PE-V3MN14 and 26 (containing glutamic acid 553 and having the ability to ADP-ribosylate elongation factor 2) and comparing their activity with wtPE in cytotoxicity assays.

Human A431 (epidermoid carcinoma) cells were seeded in 24-well tissue culture plates at  $1 \times 10^5$  cells/well in RPMI 1640 media supplemented with 5% fetal bovine serum. After 24 h, cells were treated for 18 h at 37°C with 4-fold dilutions of either wtPE or toxic forms (with a glutamic acid residue at position 553 and capable of ADP-ribosylating elongation factor 2) of the chimeric proteins. Inhibition of protein synthesis was assessed by monitoring the incorporation of  $^3\text{H}$ -leucine.

When assayed for its ability to inhibit protein synthesis, PE-V3MN26 exhibited similar toxicity to wtPE in human A431 cells (Fig. 4). PE-V3MN14 was also fully toxic. These results confirmed that the size and location of the V3 loop inserts did not impede toxin delivery to the cytosol. Further, these data suggest that the isolation, refolding and purification protocol used to prepare these chimeras resulted in the production of a correctly folded and functional protein.

### IV. IMMUNOGENICITY

To investigate their usefulness as immunogens, rabbits were injected subcutaneously with 200  $\mu\text{g}$  of either the MN or Thai-E chimeras. Rabbits were immunized subcutaneously at four sites with 200  $\mu\text{g}$  (total) of ntPE-V3MN26. The first injection was administered with complete Freund's adjuvant. All subsequent injections (at 2, 4 and 12 weeks) were given with incomplete Freund's adjuvant. Venous bleeds

were obtained weekly after the third injection and screened by immunoblotting against gp120.

In Western blots, serum samples from rabbits immunized with the ntPE-V3MN proteins exhibited a strong reactivity for immobilized recombinant gp120/MN (Fig. 5A). Reactive titers increased with time: at 6 weeks reactivity was noted at 1:200 dilution, at 12 weeks at 1:5,000 dilution and at later times reactivity could be detected at 1:25,000. These anti-V3 loop/MN sera were not reactive with gp120/Thai-E (Fig. 5A). Sera from rabbits injected with non-toxic PE (i.e. ntPE with no insert) exhibited no reactivity for gp120. Rabbits injected with the ntPE-V3Th-E produced reactive sera for gp120/Thai-E but not for gp120/MN (Fig. 5A).

Sera from rabbits immunized with ntPE-V3MN26 were characterized further. Reactivity for immobilized gp120/MN was absorbed when these sera were pre-mixed with soluble recombinant gp120/MN (Fig. 5B). This blocking activity, which was dose-dependent and maximal at 50  $\mu$ g/ml, indicated that rabbits responded primarily to V3 loop sequences that are exposed on the surface of gp120.

Sera from immunized rabbits were also found to neutralize HIV-1 infectivity in an *in vitro* assay (Fig. 6). This assay utilized MT4 cells as an indicator of HIV-1-mediated cell death (Miyoshi, I., *et al.*, 1981, *Nature* 294, 770-1). Duplicate serial dilutions of antiserum was incubated with HIV-1/MN grown in FDA/H9 cells (Popovic, M., *et al.*, 1984, *Science* 224, 497-500) and the mixture added to cells for 7 days. Viral-mediated cell death was assessed using a MTT dye assay (Robertson, G.A., *et al.*, 1988, *J Virol Methods* 20, 195-202) and spectrophotometric analysis at 570 nm. The serum 50% inhibitory concentration was calculated and reported as the neutralization titer.

Pre-immune sera did not show any protection of a human T-cell line, MT4, from killing by HIV-1 MN. Although sera at 5 weeks following immunization also showed no protection, week 8 and week 27 sera were protective against viral challenge with 50% neutralization occurring at approximately a 1:400 dilution. Based upon the immunization schedule used, week 5 sera reflected the response in animals immunized and boosted once, while week 8 sera was from animals boosted twice and week 27 sera came from animals boosted three times. MT4 cell survival values obtained for sera dilutions of less than 1:100 for the week 8 and week 27 bleeds were greater than the unchallenged cell control used for normalization. This was likely due to stimulation



by growth factors present in the rabbit sera. The data suggest that the immune response following subcutaneous injections of ntPE-V3 loop chimeras can result in the production of neutralizing antibodies.

## 5 V. NEUTRALIZATION OF INFECTIVITY

Antibodies elicited by the chimeric immunogen were shown to have the ability to neutralize infectivity of HIV-1 in viral growth assays where suppression of p24 production was used as an indicator of HIV neutralization. Clinical isolates corresponding to subtype B, RVL05, and subtype E, Th92009, were incubated with  
10 dilutions of rabbit sera and cultured in PBMCs for a total of 5 days.

One assay utilized MT4 cells as an indicator of HIV-1-mediated cell death. I. Miyoshi et al. (1981) *Nature* 294:770-771. Duplicate serial dilutions of antiserum were incubated with HIV-1/MN and grown in FDA/H9 cells and the mixture added to MT4 cells for 7 days. M. Popovic et al. (1984) *Science* 224:497-500. Viral-mediated  
15 cell death was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye assay and spectrophotometric analysis at 570 nm. G.A. Robertson et al. (1988) *J. Virol. Methods* 20:195-202. The serum 50% inhibitory concentration was calculated and reported as the neutralization titer.

A second assay used p24 production of as an indicator of viral growth. T. Wrin et al. (1995) *J. Virol.* 69:39-48. Primary virus was first titrated to determine the  
20 amount that reproducibly yielded significant but submaximal amounts of p24. Virus preparations were incubated for 1 h at 37° C with various dilutions of rabbit sera, either immune or pre-bleed, and this mixture was then added in quadruplicate to  $2.5 \times 10^5$  PBMCs. The culture continued for 3 days at which time cells were washed and V3  
25 Loop-Toxin Chimeras 9952 resuspended in medium containing interleukin 2. Accumulation of p24 was detected by an ELISA.

Because the sera taken from one of the rabbits immunized with ntPE-V3MN26 neutralized virus in the MT4 assay at a dilution of 1:400, this serum was used to evaluate activity against the clinical isolates. A serum sample taken at 24 weeks  
30 exhibited neutralizing activity against both a B and E subtype isolate (see Fig. 14). No neutralizing activity was seen with the pre-bleed sera from the same rabbit.

## VI. ELICITATION OF IgA-MEDIATED IMMUNE RESPONSE

Mucosal inoculation by a PE-like chimeric immunogen containing 26 amino acids of the V3 loop of gp120 of HIV-1 induced both a humoral and cell-mediated immune response against HIV-1. A toxic version of this chimera was capable of killing a human intestinal cell line, Caco-2, grown as confluent monolayers. A non-lethal form of the chimera was administered to mice either subcutaneously or at vaginal, rectal, gastric or nasal mucosal surfaces. Subsequent boostings were performed at these various mucosal surfaces of by subcutaneous administration. Measurement of MNgp120-specific antibodies in serum and saliva samples demonstrated both IgA and IgG responses in every group of mucosal and subcutaneous administration. These results demonstrate that the PE-like chimeric immunogens of this invention can enter epithelial cells, be trafficked similarly to native toxin, transport across an intact epithelial barrier and induce the production of both IgA and IgG antibodies.

### A. PE-Like Chimeric Immunogens

PE-like chimeras used in these experiments are described in Example I. The structural gene encoding native (toxic) PE was modified to delete the Ib region and provide a unique PstI site for the insertion of 26 amino acid V3 loop sequences. Non-toxic versions of PE-V3 loop chimeras were prepared which lacked the glutamic acid residue at position 553 ( $\Delta E553$ ) and thus has no ADP-ribosylating activity. All PE-V3 loop chimeric proteins were expressed in *E coli* BL21( $\lambda$ DE3) using the T7 promoter/T7 polymerase system. IPTG (1.0 mM for 90 min) was added to enhance protein expression. PE-V3 loop proteins were isolated from inclusion bodies and purified by successive rounds of anion exchange chromatography and a final gel filtration.

### B. Cell-based Studies

A toxic version of the *Pseudomonas* exotoxin (PE) chimera containing 26 amino acids of the V3 loop of MN gp120 (tPE-MN26) was applied to the apical surface of confluent monolayers of polarized Caco-2 cells. Caco-2 cells were cultured and maintained as previously described (W. Rubas *et al.* (1996) "Flux measurements across Caco-2 monolayers might predict transport in human large intestinal tissue" *J. Pharm. Sci.* 85:165-169) on prewetted (PBS, 15 min. outside and then inside) collagen-coated polycarbonate filter supports (Snapwells™). Culture media was changed every other day

and confluent monolayers were used on day 25 post seeding and at passage 30-35. Toxic versions of PE and PE-V3 loop chimeras were added to the apical surface in culture media. After 24 h of continued incubation at 37 °C, Caco-2 monolayers were washed thrice with PBS to remove serum esterase activities and incubated with calcein AM and ethidium homodimer to determine live/dead cell ratio (LIVE/DEAD® Eukolight kit; Molecular Probes, Inc., Eugene, OR).

The chimera killed these intestinal epithelial cells with a potency similar to that of authentic PE (Fig. 8). Cell viability was measured as the ratio of live and dead cells.

A non-toxic ( $\Delta 553$ ) chimera (ntPE-V3MN26) was used in all subsequent immunization studies to examine the ability of ntPE-V3MN26 to block the toxic actions of PE on Caco-2 monolayers (Fig. 8). Thus, the results of Figure 8 show that the incorporation of 26 amino acids of the V3 loop of MNgp120 (ntPE-V3MN26) in place of the endogenous Ib loop of PE does not alter the ability of the PE chimera to be taken up and processed by polarized, confluent epithelial cells. This ability of the PE-V3 loop chimera to be taken up and processed by epithelial cells is important against a pathogen such as HIV-1 which can infect and alter the function of human intestinal epithelial cells. D.M. Asmuth *et al.* (1994) "Physiological effects of HIV infection on human intestinal epithelial cells: an *in vitro* model for HIV enteropathy" *AIDS* 8:205-211.

### C. Immunization Protocols

Female balb-c mice were obtained from Simonsen at 6 - 8 weeks of age and quarantined for 2 weeks prior to study. Animals were placed into one of 6 groups which were inoculated 3 times at two week intervals. The animals were maintained on ad lib food and water. Animal groups were immunized as follows: (1) oral, oral, oral; (2) vaginal, vaginal, vaginal; (3) rectal, rectal, rectal; (4) vaginal, oral, oral; (5) rectal, oral, oral; and (5) subcutaneous, subcutaneous, subcutaneous. Each oral inoculation used 40  $\mu$ g of PE-V3 loop chimera in 200  $\mu$ l of PBS containing 0.05% Tween 20, 1 mg/ml BSA and 0.2 M NaHCO<sub>3</sub> (pH = 8.1). All vaginal, rectal and subcutaneous inoculations contained 20  $\mu$ g PE-V3 loop chimera in 20  $\mu$ l of PBS containing 0.05% Tween 20.

#### D. Antibody Titers

Following intraperitoneal injection of 0.1 mg pilocarpine, mouse saliva (typically 50  $\mu$ l) was collected using polypropylene Pasteur pipettes and placed into polypropylene tubes. Serum samples (100  $\mu$ l) were obtained from periorbital bleeds using serum separator tubes. Collected serum and saliva samples were stored at -70 °C until analysis. A gp120-specific ELISA was performed using Costar 9018 E.I.A./R.I.A. plates coated with gp120. Following washing with PBST (PBS containing 0.05% Tween 20 and 0.01% thimerosal), plates were blocked with assay buffer (PBST containing 0.5% BSA). A subsequent washing was performed prior to serum or saliva sample introduction (100  $\mu$ l/well). Bound immunoglobulins were tagged using biotinylated whole goat antibodies which selectively recognized either mouse IgA or mouse IgG (Amersham). A mouse monoclonal antibody denoted 1F12 (Genentech, Inc.) was used as a positive control for IgG assays. No gp120-specific mouse IgA was available as a positive standard. ExtrAvidin<sup>®</sup> peroxidase conjugate (Sigma), 2,2'-azino-bis(2ethylbenzthiazoline-6-sulfonic acid (Sigma) and a phosphate-citrate buffer containing urea and hydrogen peroxide were used to quantitate bound antibody at 405 nm.

Non-toxic PE-V3MN26 was delivered to balb-c mice in combinations of oral gavage, application to the vaginal mucosa, application to the rectal mucosa or by subcutaneous injection. Serum and saliva samples were collected one, two and three months after the initial inoculation from each dosing group and analyzed by ELISA to determine IgG and IgA antibody titers specific for MN gp120. Pre-immune saliva and serum samples showed no significant background reaction in these gp120-specific ELISAs. Measurable quantities of gp120-specific IgG were observed in the sera of all dosing groups (Fig. 9). Although the IgG response observed was initially greatest in the subcutaneous group, all groups ultimately demonstrated strong serum IgG responses. Groups that were exposed orally to the ntPE-V3MN26 also appeared to obtain an IgG response faster than those groups exposed only at the vaginal or rectal mucosa. Compared to a mouse monoclonal IgG<sub>1</sub> which selectively recognizes the V3 loop of MNgp120, the highest measured levels in each of the groups of gp120-specific IgG were between 5-25  $\mu$ g/ml sera.

IgA antibodies appear to contribute to resistance against both strict mucosal pathogens and invasive agents which go on to cause systemic disease after mucosal colonization. R.I. Walker *et al.* (1994) "New strategies for using mucosal

vaccination to achieve more effective immunization" *Vaccine* 12:387-400. An ELISA was used to determine gp120-specific IgA levels in collected saliva samples as an index of mucosal antibody response. Since there is no MN gp120-specific monoclonal IgA available, values obtained by ELISA were only compared between groups and not characterized as absolute levels. Saliva samples from all 6 dosing groups contained gp120-specific IgA (Fig. 10). The strongest IgA response was observed in animals which received an initial vaginal dose and subsequent oral doses of PE-V3 loop chimera. It was interesting that animals which received only subcutaneous injections demonstrated IgA levels comparable to some of those observed in groups receiving only mucosal exposure of the chimera. This may be related to issues of the antibodies used in the IgA ELISA. Regardless, these results show that both mucosal and systemic immunity can be induced by mucosal immunization similar to that observed previously with oral immunization using pertussis toxin. M. J. Walker, *et al.* (1992) "Specific lung mucosal and systemic immune responses after oral immunization of mice with *Salmonella typhimurium* aro A, *Salmonella typhi* Ty21a, and invasive *Escherichia coli* expressing recombinant pertussis toxin S1 subunit" *Infect. Immun.* 60:4260.

HIV-1 subunit vaccines have been reported to only produce an IgG response following subcutaneous administration (M. B. Vasudevachari *et al.* (1992) "Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160" *J. Acquir. Immune Defic. Syndr.* 5:817-821) or both IgG and IgA following intramuscular injection (G. J. Gorse *et al.* (1996) "Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine" *Clin. Diagnostic Lab. Immunol.* 3:769-773.). Although those authors suggested that maximizing the production of mucosal antibodies will be important for an HIV-1 vaccine, it is unclear, however, if the IgA antibodies detected were secretory. It is likely that sIgA was the primary form of IgA in saliva samples and that dimeric IgA was the primary form in serum samples in those as well as the present studies. The IgA-binding reagent used presently was raised against serum IgA and thus may have provided a bias in IgA measurements. Thus the IgA levels measured in serum may only appear greater than saliva levels due to a lower affinity for sIgA than dimeric IgA. The IgA values given in the present study, therefore, are only presented on a relative scale.

A number of factors released by Th1 and Th2 cells have been shown to regulate IgA responses (J. R. McGhee *et al.* (1993) "New perspectives in mucosal

immunity with emphasis on vaccine development" *Seminars in Hematology*. 30:3-15). For example, in the presence of IL-5, IL-2 synergizes with TGF- $\beta$  to augment IgA synthesis, leading to the prospect of pharmacologically manipulating the immune response. The form of antigen presentation, however, is dictated significantly by the fate of the immunogen. Epithelial cells at mucosal surfaces, which have the LRP receptor to bind and internalize ntPE-V3MN26, have been shown to express MHC class II proteins and class II can efficiently reach the surface of cells for antigen presentation from a lysosomal origin (V. G. Brachet *et al.* (1997) "Ii chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes" *J. Cell Biol.* 137:51-65). Thus, ntPE-V3MN26 can be delivered by MHC class II structures onto the cell surface of epithelial cells. Alternatively, if the immunogen crosses the mucosal barrier and reaches a professional antigen presentation cell in the underlying lamina propria in an intact form, it should induce a Th2 response and result in a MHC class I-restricted antigen presentation.

## VII. MEMORY RESPONSE ELICITED BY MUCOSAL ADMINISTRATION OF CHIMERIC IMMUNOGEN

Mucosal administration of ntPE-V3MN26 produced a significant memory response characterized by combination of serum IgG isotypes of both Th1 and Th2 pathways. Since the Th2 response has been proposed to be advantageous for neutralizing viruses and the cytotoxic immune responses associated with Th1 events may be required for effective immune responses against intracellular viruses (J.R. McGhee *et al.* (1994) *Reprod. Fertil. Dev.* 6:369-379), these results suggest that the mucosal immunization with ntPE-V3MN26 provided the types of responses desired for protection against HIV-1 infection (G.L. Ada *et al.* (1997) *AIDS Res. Hum. Retroviruses* 13:205-210).

### A. Materials And Methods

#### 1. Reagents

The structure and preparation of the ntPE-V3MN26 used in these studies is described herein. MNgp120 and the 1F12 monoclonal antibody recognizing the V3 loop of MNgp120 were prepared at Genentech, Inc. (South San Francisco, CA). Biotin-labeled goat antibodies raised against either mouse IgG or mouse IgA were purchased from Amersham Life Sciences (Arlington Heights, IL). Biotinylated rat antibodies

recognizing mouse IgG<sub>1</sub>, IgG<sub>2a</sub>, IgG<sub>2b</sub>, IgG<sub>3</sub> and IgE were obtained from Pharmingen (San Diego, CA).

## 2. Immunization protocols and samples collection

5 Female BALB/c mice were obtained at 6-8 weeks of age and quarantined for 2 weeks prior to study and maintained throughout the study on ad lib food and water. Animals were randomly assigned to groups (n = 6) which received combinations of oral, vaginal, rectal or subcutaneous dosings. Oral inoculations were performed by oral gavage of 200  $\mu$ l of PBS containing 0.05% Tween 20, 1 mg/ml BSA, 0.2 M NaHCO<sub>3</sub> (final pH = 8.1) and 40  $\mu$ g of ntPE-V3MN26. Vaginal, rectal, and subcutaneous  
10 inoculations contained 20  $\mu$ g ntPE-V3MN26 in 20  $\mu$ l of PBS containing 0.05% Tween 20. Mouse saliva (typically 50-100  $\mu$ l) was collected over approximately 10 min using polypropylene Pasteur pipettes following hypersalivation induced by intraperitoneal injection of 0.1 mg pilocarpine per animal. Serum samples (100  $\mu$ l) were obtained from  
15 periorbital bleeds using serum separator tubes. Collected serum and saliva samples were stored at -70 °C until analysis.

In a separate study, mice were subcutaneously injected with 20  $\mu$ g ntPE-V3MN26 or 20  $\mu$ g ntPE and boosted at 2 and 7 weeks. One set of animals receiving ntPE-V3MN26 (n = 3) and the animals receiving ntPE (n = 2) were simultaneously  
20 dosed with 40  $\mu$ l of Freund's complete adjuvant initially and 40  $\mu$ l of Freund's incomplete adjuvant at weeks 2 and 7. A set of animals (n = 3) dosed with 20  $\mu$ g of ntPE-V3MN26 formulated in 40  $\mu$ l of normal saline served as a control. Serum samples (100  $\mu$ l) were obtained on a weekly basis and stored as described above.

## 25 3. Measurement of antibody responses

Anti-gp120-specific antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Briefly, Costar 9018 E.I.A./R.I.A. 96-well plates were coated with 1  $\mu$ g/well of MNgp120, washed thrice with PBS containing 0.05% Tween 20 (v/v) and then blocked overnight at 4° C with PBS containing 1% BSA. After washing  
30 with PBS/Tween 20, plates were incubated with dilutions of serum or saliva samples (diluted with PBS/Tween 20 containing 0.1% BSA). The plates were incubated for 2 h at room temperature with gentle agitation, then washed thrice with PBS/Tween 20 and incubated with a biotin-conjugated goat anti-mouse IgA or IgG or, to determine IgG

subclass or IgE responses, with biotin-conjugated rat anti-mouse IgG1, IgG2a, IgG2b, IgG3, or IgE for 1 h using the same incubation conditions. After washing with PBS/Tween 20, horseradish peroxidase-conjugated streptavidin was added. Bound antibodies were visualized by ExtrAvidin<sup>®</sup> peroxidase conjugate (Sigma), 2,2'-azino-bis(2ethylbenzthiazoline-6-sulfonic acid (Sigma) and a phosphate-citrate buffer containing urea and hydrogen peroxide were used to quantitate bound antibody at 405 nm.

## B. Results

### 1. IgA antibody responses to ntPE-V3MN26

Animals were inoculated (n = 6/group) by a variety of routes with ntPE-V3MN26 followed by 2 boosts on days 14 and 21 and then at month 16. Animals received ntPE-V3MN26 either orally (PO), vaginally (V), rectally (R), vaginally and orally (V/PO), rectally and orally (R/PO), or subcutaneously (SC). Saliva samples collected at 30, 60 and 90 days and then again at 16.5 months were analyzed for antigen-specific IgA (Fig. 11). Without an anti-V3 loop IgA antibody to standardize the assays, responses were normalized against one strongly positive sample. Values were reported on an arbitrary scale of antigen-specific IgA units. All dosing groups demonstrated comparable salivary IgA responses at 30 and 60 days. By 90 days, the strongest salivary IgA response was observed in the group which received an initial vaginal dose and subsequent oral boosts. At 16.5 months the all oral, all vaginal and all rectal groups showed the greatest levels of antigen-specific salivary IgA. Responses of the combined mucosal inoculation groups (vaginal/oral and rectal/oral) were comparable to those observed in the group dosed subcutaneously.

To insure that these salivary IgA responses reflected antigen-specific binding and not a non-specific binding to salivary components, pre-immune saliva samples were evaluated and a study was performed in which a mixture of V3 loop peptide and ntPE was administered to mice. The studies showed that undiluted pre-immune saliva samples did not demonstrate a measurable background in the ELISA format. Also, animals dosed simultaneously with ntPE and an unconjugated V3 loop constrained by a disulfide bond did not have measurable MNgp120-specific IgA levels. These results indicate that there was little or no non-specific cross-reactivity in the ELISA.



No detectable antigen-specific serum IgA responses were observed in any of the dosing groups at the 1, 2 or 3 month sampling times. However, at 16.5 months, sera collected from all groups demonstrated antigen-specific IgA (Table 1). It is possible that the ability to detect serum IgA at this time may have been due to a heightened total immune response rather than a specific stimulation. Interestingly, the relative serum IgA levels did not correlate with salivary IgA levels. For example, rectal/oral combination inoculations yielded one of the weaker memory salivary IgA responses but the strongest memory serum IgA response (Table 1, Fig. 11). The all oral, all vaginal or all rectal groups, which provided the greatest salivary IgA responses at 16.5 months had some of the weakest serum IgA responses at this time. Unlike mucosal administration of ntPE-V3MN26 where opposing levels in saliva and serum were the norm, subcutaneous inoculations of ntPE-V3MN26 produced a moderate IgA response in both the saliva and serum of mice (Table 1, Fig. 11). Whatever the stimulus of IgA production, the antigen-specific serum IgA levels were transient. At the 22 month sampling, just two animals of the rectal/oral group represented the only positives for measurable serum IgA recognizing MNgp120. No other groups, even the subcutaneous injection group, showed any detectable serum IgA levels at this time point.

TABLE 1. Immunization with ntPE-V3MN26 stimulates the production of antigen-specific serum IgA and salivary IgG in Mice

Immunization schedule <sup>a</sup>	Serum IgA <sup>b</sup> (arbitrary units)	Salivary IgG <sup>c</sup> ( $\mu$ g/ml)
PO/PO/PO/PO	0.233 $\pm$ 0.074	10.9 $\pm$ 2.2
V/V/V/V	0.172 $\pm$ 0.061	9.52 $\pm$ 1.6
R/R/R/R	0.178 $\pm$ 0.042	9.93 $\pm$ 1.7
V/PO/PO/PO	0.160 $\pm$ 0.021	9.90 $\pm$ 1.3
R/PO/PO/PO	0.450 $\pm$ 0.128	11.0 $\pm$ 0.49
SC/SC/SC/SC	0.273 $\pm$ 0.078	7.1 $\pm$ 0.63

<sup>a</sup> Immunizations were performed at days 0, 14, 21 and at month 16 to animals either orally (PO) vaginally (V), rectally (R) or subcutaneously (SC).

<sup>b</sup> MNgp120-specific IgA levels were measured by ELISA at 16.5 months and normalized against a single sample standard and reported in arbitrary units.

<sup>c</sup> MNgp120-specific IgG levels were measured by ELISA at 16.5 months and calibrated against a mouse monoclonal antibody (1F12) which recognizes the V3 loop of the protein.

## 2. IgG antibody responses to ntPE-V3MN26

Serum and salivary antigen-specific IgG responses, measured by ELISA, were standardized using a mouse monoclonal antibody (1F12) which recognizes the V3 loop of MNgp120. The assay was linear over the range of 0.05 - 2.5  $\mu$ g for 1F12 and pre-immune sera and salivas were negative in the ELISA format. Although the IgG response produced by an initial inoculation followed by two boosts was ultimately greatest in the subcutaneous injection group, all mucosal inoculation groups demonstrated strong serum IgG responses at 30, 60 and 90 days (Fig. 12). Two weeks after an ntPE-V3MN26 boost at month 16 the subcutaneous injection group had the highest serum IgG memory response. All mucosal groups also showed strong memory responses at this time (Fig. 12). However, by month 22 antigen-specific serum IgG titers had decreased in all groups.

## 3. Comparison of serum and saliva IgG and IgA levels

Previous studies have suggested that serum IgG can transudate onto mucosal surfaces, possibly providing some form of immune protection. M.B. Vasudevachari et al. (1992) *J. Acquir. Immune Defic. Syndr.* 5:817-821. Others have not been able to demonstrate such a transudative event. E.-L. Johansson et al. (1998) *Infect. Immun.* 66:514-520. In these studies, antigen-specific IgG was not observed in saliva samples at months 1, 2 and 3 but rose to detectable levels following a boost at month 16 (Table 1). All mucosally dosed animal groups had comparable salivary IgG responses at this time which were greater than that observed for the animals receiving subcutaneous ntPE-V3MN26 (Table 1). This lack of correlation between relative serum and saliva levels of antigen-specific IgG (Fig. 12, Table 1) suggests a separation of the serum and salivary IgG pools resulting from this memory response. Thus, it appears that the IgG present in saliva in the studies may have resulted, to a significant extent, from local antibody production rather than a "spill-over" from circulating serum antibodies.

#### 4. Serum IgG isotype responses to ntPE-V3MN26

In mice, induction of a Th1 response typically leads to the production of IgG2a and IgG3 by B cells while a Th2 response results in IgG1 and possibly IgE production. A.K. Abbas et al. (1996) *Nature* 383:787-793. The development of either a Th1 or Th2 response is driven by specific cytokines such as interferon- $\gamma$  and IL-4. Introduction of ntPE-V3MN26 either systemically through subcutaneous injection or via application at oral, vaginal or rectal tissues led to the development of an antigen-specific serum IgG response. The IgG isotype population of these sera samples was investigated and it was found that the MNgp120-specific response was dominated ( $\sim 55\%$ ) by IgG1. Lesser and comparable amounts of antigen-specific IgG2a ( $\sim 20\%$ ) and IgG2b ( $\sim 20\%$ ) were found along with low amounts ( $\sim 5\%$ ) of IgG3. No antigen-specific IgE was detected. These results suggest that subcutaneous administration of ntPE-V3MN26 induces both Th1 and Th2 responses in BALB/c mice with the Th2 phenotype dominating.

#### VIII. EVALUATION OF ntPE-V3MN26 AS AN ADJUVANT

Adjuvants can act to facilitate the presentation of an antigen and/or activate the immune response at the site of inoculation. F.R. Vogel et al. (1995) *A compendium of vaccine adjuvants and excipients*, p. 141-228. In M. F. Powell, and M. J. Newman (ed.), *VACCINE DESIGN: THE SUBUNIT AND ADJUVANT APPROACH*, vol. 6. Plenum Press, New York. Recognized as one of the most potent adjuvants available, Freund's adjuvant is a mixture of mineral oil, surfactant and *Mycobacterium tuberculosis*. A study to assess the efficiency of serum IgG induction by ntPE-V3MN26 was performed by injecting mice subcutaneously with ntPE-V3MN26 and Freund's complete adjuvant initially, boosting with ntPE-V3MN26 and incomplete adjuvant after 14 and 49 days, and then comparing IgG serum responses to those of animals receiving ntPE-V3MN26 without Freund's adjuvant (Fig. 13). Animals receiving the same subcutaneous dosing regime of ntPE-V3MN26 with normal saline instead of Freund's adjuvant exhibited approximately one-third the antigen-specific immune response that observed in animals receiving this chimera along with Freund's adjuvant. The level of response to ntPE-V3MN26 over this time frame was similar to that observed in the subcutaneous injection group graphed in Fig. 12 at months 1, 2 and 3, suggesting a fairly consistent outcome for this form of chimera delivery. A control where the Freund's adjuvant regimen was

injected along with a non-toxic PE which lacked the V3 loop of MNgp120 demonstrated the specificity of the immune response being measured (Fig. 13).

5       The present invention provides *Pseudomonas* exotoxin A-like chimeric immunogens and methods of evoking an immune response. While specific examples have been provided, the above description is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The scope of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the  
10       appended claims along with their full scope of equivalents.

      All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication or patent document were so individually denoted. By their citation of various references in this document Applicants do not admit that any particular  
15       reference is "prior art" to their invention.

**WHAT IS CLAIMED IS:**

- 1                   1.     A non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric  
2 immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino  
3 acids that binds to a cell surface receptor; (2) a translocation domain comprising an  
4 amino acid sequence substantially identical to a sequence of PE domain II sufficient to  
5 effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an  
6 amino acid sequence of between 5 and 1500 amino acids that encodes a non-native  
7 epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER")  
8 retention domain that comprises an ER retention sequence.
  
- 1                   2.     The immunogen of claim 1 having the amino acid sequence of PE  
2  $\Delta$ E553 except that the sequence of domain Ib of PE  $\Delta$ E553 comprises the non-native  
3 epitope between two cysteine residues of domain Ib.
  
- 1                   3.     The immunogen of claim 1 wherein the cell recognition domain is  
2 domain Ia of PE.
  
- 1                   4.     The immunogen of claim 1 wherein cell recognition domain binds  
2 to  $\alpha$ 2-macroglobulin receptor (" $\alpha$ 2-MR"), epidermal growth factor ("EGF") receptor; the  
3 IL-2 receptor; the IL-6 receptor; HIV-infected cells; a chemokine receptor; a leukocyte  
4 cell surface receptor; a ligand for the IgA receptor; or an antibody or antibody fragment  
5 directed to a receptor.
  
- 1                   5.     The immunogen of claim 1 wherein cell recognition domain  
2 comprises amino acid sequences of a growth factor or an antibody.
  
- 1                   6.     The immunogen of claim 1 wherein cell recognition domain is  
2 comprised within the ER retention domain.
  
- 1                   7.     The immunogen of claim 1 wherein the translocation domain  
2 comprises amino acids 280 to 364 of domain II of PE.

1                   8.     The immunogen of claim 1 wherein the translocation domain is  
2 domain II of PE.

1                   9.     The immunogen of claim 1 wherein the non-native epitope domain  
2 comprises a cysteine-cysteine loop that comprises the non-native epitope.

1                   10.    The immunogen of claim 1 wherein the non-native epitope domain  
2 comprises an amino acid sequence encoding a non-native epitope inserted between two  
3 cysteine residues of domain Ib of PE.

1                   11.    The immunogen of claim 1 wherein the non-native epitope domain  
2 comprises an amino acid sequence selected from CTRPNYNKRK RIHIGPGRAF  
3 YTTKNIIGTI RQAHC (SEQ ID NO:3) or CTRPSNNTRT SITIGPGQVF YRTGDIIGDI  
4 RKAYC (SEQ ID NO:4).

1                   12.    The immunogen of claim 1 wherein the ER retention domain is  
2 domain III of PE comprising the mutation  $\Delta$ E553.

1                   13.    The immunogen of claim 1 wherein the ER retention sequence  
2 comprises REDLK (SEQ ID NO:11), REDL (SEQ ID NO:12) or KDEL (SEQ ID  
3 NO:13).

1                   14.    The immunogen of claim 1 which is ntPE-V3MN14 or ntPE-  
2 V3MN26.

1                   15.    The immunogen of claim 1 wherein the non-native epitope is an  
2 epitope from a viral, bacterial or parasitic protozoan pathogen.

1                   16.    The immunogen of claim 9 wherein the non-native epitope is an  
2 epitope of a V3 loop of gp120 of HIV-1.

1                   17.    The immunogen of claim 9 wherein the non-native epitope is an  
2 epitope of a principal neutralizing loop of a retrovirus.

1                   18.     The immunogen of claim 9 wherein the non-native epitope is an  
2 epitope of a major neutralizing loop of HIV-2 or a V3 loop of gp120 of HIV-1 of at least  
3 8 amino acids including a V3 loop apex.

1                   19.     A recombinant polynucleotide comprising a nucleotide sequence  
2 encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the  
3 PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10  
4 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain  
5 comprising an amino acid sequence substantially identical to a sequence of PE domain II  
6 sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain  
7 comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a  
8 non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum  
9 ("ER") retention domain that comprises an ER retention sequence.

1                   20.     The recombinant polynucleotide of claim 19 which is an expression  
2 vector further comprising an expression control sequence operatively linked to the  
3 nucleotide sequence.

1                   21.     The recombinant polynucleotide of claim 19 having the amino acid  
2 sequence of PE wherein domain Ib of PE further comprises the non-native epitope  
3 between two cysteine residues of domain Ib.

1                   22.     A recombinant non-toxic *Pseudomonas* exotoxin A-like ("PE-like")  
2 chimeric immunogen cloning platform comprising a nucleotide sequence encoding: (1) a  
3 cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface  
4 receptor; (2) a translocation domain comprising an amino acid sequence substantially  
5 identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol;  
6 (3) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain  
7 that comprises an ER retention sequence and (4) a splicing site between the sequence  
8 encoding the translocation domain and the sequence encoding the ER retention domain.

1                   23.    The recombinant cloning platform of claim 22 which is an  
2   expression vector further comprising an expression control sequence operatively linked to  
3   the nucleotide sequence.

1                   24.    A method of producing antibodies against a non-native epitope,  
2   wherein the non-native epitope naturally exists within a cysteine-cysteine loop comprising  
3   the step of inoculating an animal with a non-toxic *Pseudomonas* exotoxin A-like ("PE-  
4   like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell  
5   recognition domain of between 10 and 1500 amino acids that binds to a cell surface  
6   receptor; (2) a translocation domain comprising an amino acid sequence substantially  
7   identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol;  
8   (3) a non-native epitope domain comprising a cysteine-cysteine loop that contains within  
9   the loop an amino acid sequence of between 5 and 1500 amino acids that encodes a non-  
10   native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum  
11   ("ER") retention domain that comprises an ER retention sequence.

1                   25.    The method of claim 24 wherein the cysteine-cysteine loop  
2   comprises no more than about 30 amino acids.

1                   26.    The method of claim 24 wherein the non-native epitope is an  
2   epitope of the V3 domain of HIV-1.

1                   27.    A vaccine comprising at least one non-toxic *Pseudomonas* exotoxin  
2   A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising:  
3   (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell  
4   surface receptor; (2) a translocation domain comprising an amino acid sequence  
5   substantially identical to a sequence of PE domain II sufficient to effect translocation to a  
6   cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of  
7   between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino  
8   acid sequence encoding an endoplasmic reticulum ("ER") retention domain that  
9   comprises an ER retention sequence.



1                   28.     The vaccine of claim 27 comprising a plurality of PE-like chimeric  
2 immunogens, each immunogen having a different non-native epitope.

1                   29.     The vaccine of claim 27 further comprising a pharmaceutically  
2 acceptable carrier.

1                   30.     The vaccine of claim 27 in the form of an immunization dose  
2 wherein the immunogen is present in an amount effective to elicit in a human subject an  
3 immune response against the non-native epitope.

1                   31.     The vaccine of claim 28 wherein the different non-native epitopes  
2 are epitopes of different strains of the same pathogen.

1                   32.     The vaccine of claim 31 wherein the non-native epitope is an  
2 epitope of the V3 loop of HIV-1 and the different strains of the same pathogen are HIV-1  
3 MN and HIV-1 Thai-E.

1                   33.     A method of eliciting an immune response against a non-native  
2 epitope in a subject, the method comprising the step of administering to the subject a  
3 vaccine comprising at least one non-toxic *Pseudomonas* exotoxin A-like ("PE-like")  
4 chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition  
5 domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a  
6 translocation domain comprising an amino acid sequence substantially identical to a  
7 sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-  
8 native epitope domain comprising an amino acid sequence of between 5 and 1500 amino  
9 acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an  
10 endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

1                   34.     The method of claim 33 wherein the non-native epitope comprises a  
2 binding motif for an MHC Class II molecule of the subject and the immune response  
3 elicited is an MHC Class-II dependent cell-mediated immune response.

1                   35.     The method of claim 33 wherein the non-native epitope comprises a  
2 binding motif for an MHC Class I molecule of the subject and the immune response  
3 elicited is an MHC Class-I dependent cell-mediated immune response.

1                   36.     The method of claim 33 wherein the non-native epitope is an  
2 epitope of the V3 domain of HIV-1.

1                   37.     The method of claim 33 wherein the vaccine is administered as a  
2 prophylactic treatment against a disease mediated by an agent bearing the non-native  
3 epitope.

1                   38.     The method of claim 33 wherein the vaccine is administered as a  
2 therapeutic treatment against a disease mediated by an agent bearing the non-native  
3 epitope.

1                   39.     A polynucleotide vaccine comprising at least one recombinant  
2 polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas*  
3 exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen  
4 comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds  
5 to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence  
6 substantially identical to a sequence of PE domain II sufficient to effect translocation to a  
7 cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of  
8 between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino  
9 acid sequence encoding an endoplasmic reticulum ("ER") retention domain that  
10 comprises an ER retention sequence.

1                   40.     A method of eliciting an immune response against a non-native  
2 epitope in a subject, the method comprising the step of administering to the subject a  
3 polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a  
4 nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like")  
5 chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition  
6 domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a  
7 translocation domain comprising an amino acid sequence substantially identical to a

8 sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-  
9 native epitope domain comprising an amino acid sequence of between 5 and 1500 amino  
10 acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an  
11 endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

1 41. The method of claim 40 wherein the recombinant polynucleotide is  
2 an expression vector comprising an expression control sequence operatively linked to the  
3 nucleotide sequence.


1 42. The method of claim 40 wherein the nucleotide sequence further  
2 encodes a mammalian secretory sequence attached to the amino terminus of the  
3 immunogen.

1 43. A method of eliciting an immune response against a non-native  
2 epitope in a subject, the method comprising the steps of transfecting cells with a  
3 recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic  
4 *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric  
5 immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino  
6 acids that binds to a cell surface receptor; (2) a translocation domain comprising an  
7 amino acid sequence substantially identical to a sequence of PE domain II sufficient to  
8 effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an  
9 amino acid sequence of between 5 and 1500 amino acids that encodes a non-native  
10 epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER")  
11 retention domain that comprises an ER retention sequence, and administering the cells to  
12 the subject.

1/14

## 1 A Pseudomonas exotoxin

## 1 B V3-loop toxin chimera




## 1 C

Protein	Ib Loop Region Amino Acid Sequence	Molecular Mass
wild-type PE	-GAANADVVS LTCPVAAGECAGPAD-	67,122 Da
ntPE-V3MN14	-GAANLHCGIHIGPGRAFYTTKCMQGPAD-	67,729 Da
ntPE-V3MN26	-GAANLHCNYNKRKRIHIGPGRAFYT TKNIIGTICMQGPAD-	68,937 Da
ntPE-V3ThE26	-GAANLHCSNNTRTSITIGPGQVFYRT GDIIGDDICMQGPAD-	68,700 Da
ntPE-FP16	-GAANLQCRLEEKKGNYVVTDHRLCLQGPAD-	67,862 Da


Figure 1.

2/14



SDS-PAGE


**FIG. 2A.**




IF12/MN

Western blot Analysis


**FIG. 2B.**



IB2/Th-E



IF12/MN




IB2/Th-E

Antibody-mediated capture of proteins


**FIG. 2C.**

3/14

3A



3B



3C

Sample	% $\alpha$ -helix*	% $\beta$ -sheet	% $\beta$ -turns	% other
wild-type PE	21	48	12	20
ntPE-V3MN14	26	46	10	19
ntPE-V3MN26	18	50	12	20

Figure 3.  
 SUBSTITUTE SHEET (RULE 26)

4/14

## Cytotoxic activity for A431 Cells






Figure 4.



**FIG. 5A.**



**FIG. 5B.**



6/14




Figure 6.

7/14




Figure 7.

8/14




Figure 8.

9/14




Figure 9.

10/14




Figure 10.

11/14

# Salivary IgA Response Induced by ntPE-MN26





Figure 11.

12/14

# Serum IgG Response to Subcutaneous Injection of ntPE-MN26




Days Post Initial Inoculation

Figure 12.

13/14

# Serum IgG Response Induced by ntPE-MN26



Months Post Initial Inoculation

Figure 13.



14/14




Figure 14.

## SEQUENCE LISTING

The nucleotide sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of *Pseudomonas* exotoxin A are:

5	GCC GAA GAA GCT TTC GAC CTC TGG AAC GAA TGC GCC AAA GCC TGC GTG Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val	48
	1 5 10 15	
10	CTC GAC CTC AAG GAC GGC GTG CGT TCC AGC CGC ATG AGC GTC GAC CCG Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro	96
	20 25 30	
15	GCC ATC GCC GAC ACC AAC GGC CAG GGC GTG CTG CAC TAC TCC ATG GTC Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val	144
	35 40 45	
20	CTG GAG GGC GGC AAC GAC GCG CTC AAG CTG GCC ATC GAC AAC GCC CTC Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu	192
	50 55 60	
25	AGC ATC ACC AGC GAC GGC CTG ACC ATC CGC CTC GAA GGC GGC GTC GAG Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu	240
	65 70 75 80	
30	CCG AAC AAG CCG GTG CGC TAC AGC TAC ACG CGC CAG GCG CGC GGC AGT Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser	288
	85 90 95	
35	TGG TCG CTG AAC TGG CTG GTA CCG ATC GGC CAC GAG AAG CCC TCG AAC Trp Ser Leu Asn Trp Leu Val Pro Ile Gly His Glu Lys Pro Ser Asn	336
	100 105 110	
40	ATC AAG GTG TTC ATC CAC GAA CTG AAC GCC GGC AAC CAG CTC AGC CAC Ile Lys Val Phe Ile His Glu Leu Asn Ala Gly Asn Gln Leu Ser His	384
	115 120 125	
45	ATG TCG CCG ATC TAC ACC ATC GAG ATG GGC GAC GAG TTG CTG GCG AAG Met Ser Pro Ile Tyr Thr Ile Glu Met Gly Asp Glu Leu Leu Ala Lys	432
	130 135 140	
50	CTG GCG CGC GAT GCC ACC TTC TTC GTC AGG GCG CAC GAG AGC AAC GAG Leu Ala Arg Asp Ala Thr Phe Phe Val Arg Ala His Glu Ser Asn Glu	480
	145 150 155 160	
55	ATG CAG CCG ACG CTC GCC ATC AGC CAT GCC GGG GTC AGC GTG GTC ATG Met Gln Pro Thr Leu Ala Ile Ser His Ala Gly Val Ser Val Val Met	528
	165 170 175	
60	GCC CAG ACC CAG CCG CGC CGG GAA AAG CGC TGG AGC GAA TGG GCC AGC Ala Gln Thr Gln Pro Arg Arg Glu Lys Arg Trp Ser Glu Trp Ala Ser	576
	180 185 190	
65	GGC AAG GTG TTG TGC CTG CTC GAC CCG CTG GAC GGG GTC TAC AAC TAC Gly Lys Val Leu Cys Leu Leu Asp Pro Leu Asp Gly Val Tyr Asn Tyr	624
	195 200 205	
70	CTC GCC CAG CAA CGC TGC AAC CTC GAC GAT ACC TGG GAA GGC AAG ATC Leu Ala Gln Gln Arg Cys Asn Leu Asp Asp Thr Trp Glu Gly Lys Ile	672
	210 215 220	
75	TAC CGG GTG CTC GCC GGC AAC CCG GCG AAG CAT GAC CTG GAC ATC AAA Tyr Arg Val Leu Ala Gly Asn Pro Ala Lys His Asp Leu Asp Ile Lys	720
	225 230 235 240	

5	CCC Pro	ACG Thr	GTC Val	ATC Ile	AGT Ser	CAT His	CGC Arg	CTG Leu	CAC His	TTT Phe	CCC Pro	GAG Glu	GGC Gly	GGC Gly	AGC Ser	CTG Leu	768
					245					250					255		
	GCC Ala	GCG Ala	CTG Leu	ACC Thr	GCG Ala	CAC His	CAG Gln	GCT Ala	TGC Cys	CAC His	CTG Leu	CCG Pro	CTG Leu	GAG Leu	ACT Glu	TTC Thr	816
				260					265					270			
10	ACC Thr	CGT Arg	CAT His	CGC Arg	CAG Gln	CCG Pro	CGC Arg	GGC Gly	TGG Trp	GAA Glu	CAA Gln	CTG Leu	GAG Glu	CAG Gln	TGC Cys	GGC Gly	864
					275					280					285		
15	TAT Tyr	CCG Pro	GTG Val	CAG Gln	CGG Arg	CTG Leu	GTC Val	GCC Ala	CTC Leu	TAC Tyr	CTG Leu	GCG Ala	GCG Ala	CGG Arg	CTG Leu	TCG Ser	912
					290					295					300		
20	TGG Trp	AAC Asn	CAG Gln	GTC Val	GAC Asp	CAG Gln	GTG Val	ATC Ile	CGC Arg	AAC Asn	GCC Ala	CTG Leu	GCC Ala	AGC Ser	CCC Pro	GGC Gly	960
					305					310					315		
25	AGC Ser	GGC Gly	GGC Gly	GAC Asp	CTG Leu	GGC Gly	GAA Glu	GCG Ala	ATC Ile	CGC Arg	GAG Glu	CAG Gln	CCG Pro	GAG Glu	CAG Gln	GCC Ala	1008
					325					330					335		
30	CGT Arg	CTG Leu	GCC Ala	CTG Leu	ACC Thr	CTG Leu	GCC Ala	GCC Ala	GCC Ala	GAG Glu	AGC Ser	GAG Glu	CGC Arg	TTC Phe	GTC Val	CGG Arg	1056
					340					345					350		
35	CAG Gln	GGC Gly	ACC Thr	GGC Gly	AAC Asn	GAC Asp	GAG Glu	GCC Ala	GGC Gly	GCG Ala	GCC Ala	AAC Asn	GCC Ala	GAC Asp	GTG Val	GTG Val	1104
					355					360					365		
40	AGC Ser	CTG Leu	ACC Thr	TGC Cys	CCG Pro	GTC Val	GCC Ala	GCC Ala	GGT Gly	GAA Glu	TGC Cys	GCG Ala	GGC Gly	CCG Pro	GCG Ala	GAC Asp	1152
					370					375					380		
45	AGC Ser	GGC Gly	GAC Asp	GCC Ala	CTG Leu	CTG Leu	GAG Glu	CGC Arg	AAC Asn	TAT Tyr	CCC Pro	ACT Thr	GGC Gly	GCG Ala	GAG Glu	TTC Phe	1200
					385					390					395		
50	CTC Leu	GGC Gly	GAC Asp	GGC Gly	GGC Gly	GAC Asp	GTC Val	AGC Ser	TTC Phe	AGC Ser	ACC Thr	CGC Arg	GGC Gly	ACG Thr	CAG Gln	AAC Asn	1248
					405					410					415		
55	TGG Trp	ACG Thr	GTG Val	GAG Glu	CGG Arg	CTG Leu	CTC Leu	CAG Gln	GCG Ala	CAC His	CGC Arg	CAA Gln	CTG Leu	GAG Glu	GAG Glu	CGC Arg	1296
					420					425					430		
60	GGC Gly	TAT Tyr	GTG Val	TTC Phe	GTC Val	GGC Gly	TAC Tyr	CAC His	GGC Gly	ACC Thr	TTC Phe	CTC Leu	GAA Glu	GCG Ala	GCG Ala	CAA Gln	1344
					435					440					445		
65	AGC Ser	ATC Ile	GTC Val	TTC Phe	GGC Gly	GGG Gly	GTG Val	CGC Arg	GCG Ala	CGC Arg	AGC Ser	CAG Gln	GAC Asp	CTC Leu	GAC Asp	GCG Ala	1392
					450					455					460		
70	ATC Ile	TGG Trp	CGC Arg	GGT Gly	TTC Phe	TAT Tyr	ATC Ile	GCC Ala	GGC Gly	GAT Asp	CCG Pro	GCG Ala	CTG Leu	GCC Ala	TAC Tyr	GGC Gly	1440
					465					470					475		
75	TAC Tyr	GCC Ala	CAG Gln	GAC Asp	CAG Gln	GAA Glu	CCC Pro	GAC Asp	GCA Ala	CGC Arg	GGC Gly	CGG Arg	ATC Ile	CGC Arg	AAC Asn	GGT Gly	1488
					485					490					495		
80	GCC Ala	CTG Leu	CTG Leu	CGG Arg	GTC Val	TAT Tyr	GTG Val	CCG Pro	CGC Arg	TCG Ser	AGC Ser	CTG Leu	CCG Pro	GGC Gly	TTC Phe	TAC Tyr	1536
					500					505					510		

	CGC	ACC	AGC	CTG	ACC	CTG	GCC	GCG	CCG	GAG	GCG	GCG	GGC	GAG	GTC	GAA	1584
	Arg	Thr	Ser	Leu	Thr	Leu	Ala	Ala	Pro	Glu	Ala	Ala	Gly	Glu	Val	Glu	
			515					520					525				
5	CGG	CTG	ATC	GGC	CAT	CCG	CTG	CCG	CTG	CGC	CTG	GAC	GCC	ATC	ACC	GGC	1632
	Arg	Leu	Ile	Gly	His	Pro	Leu	Pro	Leu	Arg	Leu	Asp	Ala	Ile	Thr	Gly	
		530					535					540					
10	CCC	GAG	GAG	GAA	GGC	GGG	CGC	CTG	GAG	ACC	ATT	CTC	GGC	TGG	CCG	CTG	1680
	Pro	Glu	Glu	Glu	Gly	Gly	Arg	Leu	Glu	Thr	Ile	Leu	Gly	Trp	Pro	Leu	
	545					550					555					560	
15	GCC	GAG	CGC	ACC	GTG	GTG	ATT	CCC	TCG	GCG	ATC	CCC	ACC	GAC	CCG	CGC	1728
	Ala	Glu	Arg	Thr	Val	Val	Ile	Pro	Ser	Ala	Ile	Pro	Thr	Asp	Pro	Arg	
					565					570					575		
20	AAC	GTC	GGC	GGC	GAC	CTC	GAC	CCG	TCC	AGC	ATC	CCC	GAC	AAG	GAA	CAG	1776
	Asn	Val	Gly	Gly	Asp	Leu	Asp	Pro	Ser	Ser	Ile	Pro	Asp	Lys	Glu	Gln	
			580					585						590			
25	GCG	ATC	AGC	GCC	CTG	CCG	GAC	TAC	GCC	AGC	CAG	CCC	GGC	AAA	CCG	CCG	1824
	Ala	Ile	Ser	Ala	Leu	Pro	Asp	Tyr	Ala	Ser	Gln	Pro	Gly	Lys	Pro	Pro	
			595					600					605				
30	CGC	GAG	GAC	CTG	AAG												1839
	Arg	Glu	Asp	Leu	Lys												
		610															

# INTERNATIONAL SEARCH REPORT

Int ernational Application No  
PCT/US 98/14341

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 A61K39/21 C07K16/10 A61K39/104 C12N15/70  
A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>EP 0 439 954 A (SERAGEN, INC.) 7 August 1991</p> <p>see page 2, line 45 - page 3, line 50 see page 4, line 1 - line 40 see page 5, line 23 - line 53 see page 11, line 35 - page 12, line 26 --- -/--</p>	<p>1-5, 7, 8, 12, 15-20, 22-24, 26-43</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Date of mailing of the international search report

10/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

# INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 98/14341

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>VIJAY . CHAUDHARY ET AL.: "Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 1, January 1990, pages 308-312, XP002079997 WASHINGTON US see abstract see page 308, right-hand column, paragraph 2</p>	1,3-5,7, 8,15-20, 22-24, 26-43
Y	<p>MAJA LUKAC ET AL.: "Toxoid of Pseudomonas aeruginosa Exotoxin A generated by deletion of an active site residue"</p> <p>INFECTION AND IMMUNITY., vol. 56, no. 11, November 1988, pages 3095-3098, XP002080494 WASHINGTON US see abstract</p>	2,12
A	<p>S.J. CRYZ JR ET AL.: "Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine"</p> <p>VACCINE., vol. 13, no. 1, January 1995, pages 67-71, XP002079998 GUILDFORD GB cited in the application see abstract see page 67, left-hand column, paragraph 1 - right-hand column, paragraph 1 see page 69, left-hand column, paragraph 2 see page 70, right-hand column, paragraph 2 - page 71, left-hand column, paragraph 1</p>	
P,X	<p>DAVID J. FITZGERALD ET AL.: "Characterization of V3 loop-Pseudomonas Exotoxin chimeras"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 16, 17 April 1998, pages 9951-9958, XP002079999 MD US see the whole document</p>	1-43
T	<p>WO 98 20135 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA) 14 May 1998 see page 4, line 4 - line 32 see page 22, line 40 - line 50 see page 23, line 22 - page 25, line 2 see page 27, line 18 - page 29, line 5 see page 31, line 2 - page 32, line 12</p>	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 14341

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 24-26, 33-38, and 40-43  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int tional Application No

PCT/US 98/14341

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 439954 A	07-08-1991	AU 657087 B	02-03-1995
		AU 7168991 A	24-07-1991
		AU 8032194 A	27-04-1995
		CA 2071969 A	23-06-1991
		JP 5502880 T	20-05-1993
		WO 9109871 A	11-07-1991
		US 5668255 A	16-09-1997
WO 9820135 A	14-05-1998	AU 5247498 A	29-05-1998



# INTERNATIONAL COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 03 March 1999 (03.03.99)	
<b>International application No.</b> PCT/US98/14341	<b>Applicant's or agent's file reference</b> 15280-3101PC
<b>International filing date (day/month/year)</b> 10 July 1998 (10.07.98)	<b>Priority date (day/month/year)</b> 11 July 1997 (11.07.97)
<b>Applicant</b> FITZGERALD, David, J.	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
10 February 1999 (10.02.99)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer</p> <p>Jean-Marie McAdams</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

HOME COPY

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No. **PCT/US 98/14341**

International Filing Date **(10.07.98) 10 JUL 1998**

**PCT INTERNATIONAL APPLICATION RO/US**  
Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) **15280-3101PC**

**Box No. I TITLE OF INVENTION**

PSEUDOMONAS EXOTOXIN, A-LIKE CHIMERIC IMMUNOGENS

**Box No. II APPLICANT**

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

THE GOVERNMENT OF THE UNITED STATES as represented  
by the Secretary of the Department of Health and  
Human Services

Bethesda, Maryland 20892  
United States of America

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (that is, country) of nationality: **US**

State (that is, country) of residence: **US**

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

**Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

FITZGERALD, David J.  
1202 Azalea Drive  
Rockville, Maryland 20850  
United States of America

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality: **US**

State (that is, country) of residence: **US**

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

**Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: ☒ agent ☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

STORELLA, John R.; WEBER, Kenneth A. & CHAMBERS, Guy A.  
TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
United States of America

Telephone No.

(415) 576-0200

Facsimile No.

(415) 576-0300

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

**Box No.V DESIGNATION OF STATES**

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

**Regional Patent**

- ☒ **AP** ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA** Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA** OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

**National Patent (if other kind of protection or treatment desired, specify on dotted line):**

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> <b>AL</b> Albania                               | <input checked="" type="checkbox"/> <b>LS</b> Lesotho  |
| <input checked="" type="checkbox"/> <b>AM</b> Armenia                               | <input checked="" type="checkbox"/> <b>LT</b> Lithuania  |
| <input checked="" type="checkbox"/> <b>AT</b> Austria                               | <input checked="" type="checkbox"/> <b>LU</b> Luxembourg   |
| <input checked="" type="checkbox"/> <b>AU</b> Australia                             | <input checked="" type="checkbox"/> <b>LV</b> Latvia   |
| <input checked="" type="checkbox"/> <b>AZ</b> Azerbaijan                            | <input checked="" type="checkbox"/> <b>MD</b> Republic of Moldova                                |
| <input checked="" type="checkbox"/> <b>BA</b> Bosnia and Herzegovina                | <input checked="" type="checkbox"/> <b>MG</b> Madagascar   |
| <input checked="" type="checkbox"/> <b>BB</b> Barbados                              | <input checked="" type="checkbox"/> <b>MK</b> The former Yugoslav Republic of Macedonia          |
| <input checked="" type="checkbox"/> <b>BG</b> Bulgaria                              | <input checked="" type="checkbox"/> <b>MN</b> Mongolia   |
| <input checked="" type="checkbox"/> <b>BR</b> Brazil                                | <input checked="" type="checkbox"/> <b>MW</b> Malawi   |
| <input checked="" type="checkbox"/> <b>BY</b> Belarus                               | <input checked="" type="checkbox"/> <b>MX</b> Mexico   |
| <input checked="" type="checkbox"/> <b>CA</b> Canada                                | <input checked="" type="checkbox"/> <b>NO</b> Norway   |
| <input checked="" type="checkbox"/> <b>CH and LI</b> Switzerland and Liechtenstein  | <input checked="" type="checkbox"/> <b>NZ</b> New Zealand  |
| <input checked="" type="checkbox"/> <b>CN</b> China                                 | <input checked="" type="checkbox"/> <b>PL</b> Poland   |
| <input checked="" type="checkbox"/> <b>CU</b> Cuba                                  | <input checked="" type="checkbox"/> <b>PT</b> Portugal   |
| <input checked="" type="checkbox"/> <b>CZ</b> Czech Republic                        | <input checked="" type="checkbox"/> <b>RO</b> Romania  |
| <input checked="" type="checkbox"/> <b>DE</b> Germany                               | <input checked="" type="checkbox"/> <b>RU</b> Russian Federation                                 |
| <input checked="" type="checkbox"/> <b>DK</b> Denmark                               | <input checked="" type="checkbox"/> <b>SD</b> Sudan  |
| <input checked="" type="checkbox"/> <b>EE</b> Estonia                               | <input checked="" type="checkbox"/> <b>SE</b> Sweden   |
| <input checked="" type="checkbox"/> <b>ES</b> Spain                                 | <input checked="" type="checkbox"/> <b>SG</b> Singapore  |
| <input checked="" type="checkbox"/> <b>FI</b> Finland                               | <input checked="" type="checkbox"/> <b>SI</b> Slovenia   |
| <input checked="" type="checkbox"/> <b>GB</b> United Kingdom                        | <input checked="" type="checkbox"/> <b>SK</b> Slovakia   |
| <input checked="" type="checkbox"/> <b>GE</b> Georgia                               | <input checked="" type="checkbox"/> <b>SL</b> Sierra Leone                                       |
| <input checked="" type="checkbox"/> <b>GH</b> Ghana                                 | <input checked="" type="checkbox"/> <b>TJ</b> Tajikistan   |
| <input checked="" type="checkbox"/> <b>GM</b> Gambia                                | <input checked="" type="checkbox"/> <b>TM</b> Turkmenistan                                       |
| <input checked="" type="checkbox"/> <b>GW</b> Guinea-Bissau                         | <input checked="" type="checkbox"/> <b>TR</b> Turkey   |
| <input checked="" type="checkbox"/> <b>HR</b> Croatia                               | <input checked="" type="checkbox"/> <b>TT</b> Trinidad and Tobago                                |
| <input checked="" type="checkbox"/> <b>HU</b> Hungary                               | <input checked="" type="checkbox"/> <b>UA</b> Ukraine  |
| <input checked="" type="checkbox"/> <b>ID</b> Indonesia                             | <input checked="" type="checkbox"/> <b>UG</b> Uganda   |
| <input checked="" type="checkbox"/> <b>IL</b> Israel                                | <input checked="" type="checkbox"/> <b>US</b> United States of America, continuation-<br>in-part |
| <input checked="" type="checkbox"/> <b>IS</b> Iceland                               | <input checked="" type="checkbox"/> <b>UZ</b> Uzbekistan   |
| <input checked="" type="checkbox"/> <b>JP</b> Japan                                 | <input checked="" type="checkbox"/> <b>VN</b> Viet Nam   |
| <input checked="" type="checkbox"/> <b>KE</b> Kenya                                 | <input checked="" type="checkbox"/> <b>YU</b> Yugoslavia   |
| <input checked="" type="checkbox"/> <b>KG</b> Kyrgyzstan                            | <input checked="" type="checkbox"/> <b>ZW</b> Zimbabwe   |
| <input checked="" type="checkbox"/> <b>KP</b> Democratic People's Republic of Korea |  |
| <input checked="" type="checkbox"/> <b>KR</b> Republic of Korea                     |  |
| <input checked="" type="checkbox"/> <b>KZ</b> Kazakhstan                            |  |
| <input checked="" type="checkbox"/> <b>LC</b> Saint Lucia                           |  |
| <input checked="" type="checkbox"/> <b>LK</b> Sri Lanka                             |  |
| <input checked="" type="checkbox"/> <b>LR</b> Liberia                               |  |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

- ☐ .....
- ☐ .....

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

**Supplemental Box***If the Supplemental Box is not used, this sheet should not be included in the request.*

1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
- (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
- (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
- (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.

2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.

3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

Continuation of Box No. V:

U.S. 60/052,375; 11 JULY 1997 (11.07.97)

US

## Box No. VI PRIORITY CLAIM

☐ Further priority claims are indicated in the Supplemental Box.

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application: regional Office	international application: receiving Office
item (1) (11.07.97) 11 JULY 1997	60/052,375	US		
item (2)				
item (3)				

- ☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1)

\* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(iii)). See Supplemental Box.

## Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen: the two-letter code may be used):

ISA / EP

Request to use results of earlier search: reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)

Number

Country (or regional Office)

## Box No. VIII CHECK LIST: LANGUAGE OF FILING

This international application contains the following number of sheets:

request : 4  
description (excluding sequence listing part) : 64  
claims : 7  
abstract : 1  
drawings : 14  
sequence listing part of description : 0

Total number of sheets : 90

This international application is accompanied by the item(s) marked below:

- ☒ fee calculation sheet
- ☐ separate signed power of attorney
- ☒ copy of general power of attorney; reference number, if any: and Delegation of Authority
- ☐ statement explaining lack of signature
- ☐ priority document(s) identified in Box No. VI as item(s):
- ☐ translation of international application into (language):
- ☐ separate indications concerning deposited microorganism or other biological material
- ☐ nucleotide and/or amino acid sequence listing in computer readable form
- ☒ other (specify): Transmittal Sheet and post card


Figure of the drawings which should accompany the abstract:

Language of filing of the international application:

## Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

  
STORELLA, John R.

  
FITZGERALD, David J.

For receiving Office use only		2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
1. Date of actual receipt of the purported international application:	34 Rec'd PCT/PTO 10 JUL 1998 (10.07.98)	
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority (if two or more are competent): ISA / EP	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

Date of receipt of the record copy by the International Bureau:

For International Bureau use only

PCT

GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA,  
as represented by the Secretary, Department of Health and Human Services, hereby appoint(s):

James C. Haight  
Gloria H. Richmond  
Robert Benson  
Jack Spiegel

Susan S. Rucker  
David R. Sadowski  
Laurence J. Hyman  
Steven M. Ferguson

Stephen L. Finley  
John Peter Kim  
Larry M. Tiffany

all of the Office of Technology Transfer, National Institutes of Health, acting under authority of  
the Department of Health and Human Services, Government of the United States of America; and

Philip H. Albert, Reg. No. 35,819  
Hector A. Alicea, Reg. No. P40,891  
Randolph T. Apple, Reg. No. P36,429  
Kevin L. Bastian, Reg. No. 34,774  
Guy Chambers, Reg. No. 30,617  
Karen B. Dow, Reg. No. 29,684  
James F. Harn, Reg. No. 29,719  
M. Henry Heines, Reg. No. 28,219  
James M. Heslin, Reg. No. 29,541  
Tom Hunter, Reg. No. 38,498  
William B. Kezer, Reg. No. 37,369  
Charlie E. Kreuger, Reg. No. 30,077

Joseph Liebeshuetz, Reg. No. 37,505  
Jonathan A. Quine, Reg. No. P41,261  
Steven W. Parmelee, Reg. No. 31,990  
Timothy L. Smith, Reg. No. 35,367  
William M. Smith, Reg. No. 30,223  
Lauren L. Stevens, Reg. No. P36691  
John R. Storella, Reg. No. 32,944  
Eugenia Garrett-Wackowski, Reg. No. 37,330  
Ellen Lauver Weber, Reg. No. 32,762  
Kenneth A. Weber, Reg. No. 31,667  
Michael E. Woods, Reg. No. 33,466

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300

as agents to represent the undersigned before all the competent International Authorities in  
connection with and all international applications filed by the undersigned with the United States  
Patent & Trademark office as Receiving Office and to make or receive payments on behalf of the  
undersigned.

Address all correspondence to:

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300

The National Institutes of Health Office of Technology Transfer has been duly delegated  
responsibility for such patent matters under the authority of the Department of Health and Human  
Services Secretary Louis W. Sullivan's memorandum of May 21, 1991 appearing in the Friday,

DOCT/US  
RO/US 30 OCT 1998

June 7, 1991, Federal Register Notices at Volume 56, Number 100, pages 26418-26419, a copy of which is attached. The undersigned is authorized to exercise such authority in this matter.

Signature of the applicant:

  
(where there are several applicants, each of them must sign):

Place: ROCKVILLE, MARYLAND Date: 15 APRIL 1997

By: James C. Haight, Reg. No. 25,588  
for: Maria C. Freire, Director  
Office of Technology Transfer  
National Institutes of Health  
6011 Executive Boulevard, Suite 325  
Rockville, Maryland 20852 U.S.A.  
Telephone No. (3201) 496-7056  
Fax No. (301) 402-0220

NIHPWR03.MRG 4/97

# PCT

## FEE CALCULATION SHEET Annex to the Request

For receiving Office use only

**PCT/US 98/14341**

International application No.

**10 JUL 1998**

Date stamp of the receiving Office

Applicant's or agent's  
file reference **15280-3101PC**

Applicant

THE GOVERNMENT OF THE UNITED STATES.....

### CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE . . . . . **240.** T

2. SEARCH FEE . . . . . **1,250.** S

International search to be carried out by EP  
(If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the international search.)

### 3. INTERNATIONAL FEE

#### Basic Fee

The international application contains 90 sheets.

first 30 sheets . . . . . **455.** b1

60 x 10. = **600.** b2  
remaining sheets additional amount

Add amounts entered at b1 and b2 and enter total at B . . . . . **1,055.** B

#### Designation Fees

The international application contains max designations.

11+ x 105. = **1,155.** D  
number of designation fees amount of designation fee payable (maximum 11)

Add amounts entered at B and D and enter total at I . . . . . **2,210.** I

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT (if applicable) . . . . . **15.** P

5. TOTAL FEES PAYABLE . . . . . **3,715.**

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

**TOTAL**

☐ The designation fees are not paid at this time.

### MODE OF PAYMENT

- |   |   |   |
|---|---|---|
| <input checked="" type="checkbox"/> authorization to charge deposit account (see below) | <input type="checkbox"/> bank draft     | <input type="checkbox"/> coupons          |
| <input type="checkbox"/> cheque   | <input type="checkbox"/> cash           | <input type="checkbox"/> other (specify): |
| <input type="checkbox"/> postal money order   | <input type="checkbox"/> revenue stamps |   |

### DEPOSIT ACCOUNT AUTHORIZATION (this mode of payment may not be available at all receiving Offices)

The RO/ US ☒ is hereby authorized to charge the total fees indicated above to my deposit account.

☒ is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.

☒ is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account.

20-1430  
Deposit Account No.

10 JULY 1998  
Date (day/month/year)

John Storella  
Signature **STORELLA, John A.**

\$ 240  
1250  
  
455  
600  
1055  
  
1155  
  
2210  
  
15  
  
\$ 3715



09/462682  
1661

1645 15

# PATENT COOPERATION TREATY

## PCT

REC'D 25 OCT 1999

WIPO PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 15280-3101PC		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
<b>FOR FURTHER ACTION</b>		
International application No. PCT/US98/14341	International filing date (day/month/year) 10/07/1998	Priority date (day/month/year) 11/07/1997
International Patent Classification (IPC) or national classification and IPC C12N15/62		<b>RECEIVED</b>  MAR 23 2001
Applicant THE GOVERNMENT OF THE UNITED STATES as ....et al.		TECH CENTER 1600/2900

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 7 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  10/02/1999	Date of completion of this report  19. 10. 99
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Kalsner, I  Telephone No. +49 89 2399 8708



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/14341

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.)*:

**Description, pages:**

1-62 as originally filed

**Claims, No.:**

1-43 as received on 26/07/1999

**Drawings, sheets:**

1/14-14/14 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:  
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/14341

---

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	1-43
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-43
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-43
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

**Ad Section V: Reasoned statement with regard to novelty, inventive step or industrial applicability**

**1) Amendments**

The amendments filed with the letter received on 26 July 1999 are allowable under Art. 34(2)(b) PCT.

**2) Documents**

D1...EP-A-0439954

**3) Novelty and inventive step**

The present international application relates to a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen comprising a cell recognition domain that binds to a cell surface receptor, a translocation domain, a non-native epitope domain and a ER retention domain and to a recombinant polynucleotide encoding such protein. The recombinant chimeric protein or the polynucleotide encoding the chimeric protein are employed in methods of producing antibodies, methods of eliciting an immune response and in vaccines.

D1 is considered to represent the closest prior art. It discloses non-toxic hybrid proteins comprising a cell-binding ligand and a translocation domain of *Pseudomonas* exotoxin A and a non-native epitope domain. The chimeric protein disclosed in D1 is used to target a non-native epitope (such as e.g. enzyme, antibiotic, antigen, etc.) to a specific cell recognised by the cell binding ligand.

The difference between the present application and the disclosure of D1 lies in the structure of the chimeric protein (the hybrid of D1 does not include an ER retention signal) as well as in the intended applications of the chimeric protein.

The problem to be solved by the present application is to provide a hybrid protein in which an immunogenic epitope is included in order to elicit an immune response to this epitope.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US98/14341

None of the available prior art discloses or suggests chimeric proteins as claimed in the present application. **Claims 1-43** are thus considered to meet the requirements of Art. 33(2) and (3) PCT.

- 4) **Claims 24-26, 33-38 and 40-43** are directed to a method of treatment of the human or animal body. In this respect the following should be noted:

For the assessment of these claims on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

WHAT IS CLAIMED IS:

1. A non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.
2. The immunogen of claim 1 having the amino acid sequence of PE (SEQ ID NO:2) except that the sequence of domain Ib comprises the non-native epitope between two cysteine residues of domain Ib and amino acid Glu at position 553 is deleted.
3. The immunogen of claim 1 wherein the cell recognition domain is domain Ia of PE.
4. The immunogen of claim 1 wherein cell recognition domain binds to  $\alpha$ 2-macroglobulin receptor (" $\alpha$ 2-MR"), epidermal growth factor ("EGF") receptor; the IL-2 receptor; the IL-6 receptor; HIV-infected cells; a chemokine receptor; a leukocyte cell surface receptor; a ligand for the IgA receptor; or an antibody or antibody fragment directed to a receptor.
5. The immunogen of claim 1 wherein cell recognition domain comprises amino acid sequences of a growth factor or an antibody. 6. The immunogen of claim 1 wherein cell recognition domain is comprised within the ER retention domain.
7. The immunogen of claim 1 wherein the translocation domain comprises amino acids 280 to 364 of domain II of PE.
8. The immunogen of claim 1 wherein the translocation domain is domain II of PE.

9. The immunogen of claim 1 wherein the non-native epitope domain comprises a cysteine-cysteine loop that comprises the non-native epitope.

10. The immunogen of claim 1 wherein the non-native epitope domain comprises an amino acid sequence encoding a non-native epitope inserted between two  
5 cysteine residues of domain Ib of PE.

11. The immunogen of claim 1 wherein the non-native epitope domain comprises an amino acid sequence selected from CTRPNYNKRR RIHIGPGRAF YTTKNIIGTI RQAHC (SEQ ID NO:3) or CTRPSNNTRT SITIGPGQVF YRTGDIIGDI RKAYC (SEQ ID NO:4).

10 12. The immunogen of claim 1 wherein the ER retention domain is domain III of PE except that amino acid Glu at position 553 of SEQ ID NO:2 is deleted.

13. The immunogen of claim 1 wherein the ER retention sequence comprises REDLK (SEQ ID NO:11), REDL (SEQ ID NO:12) or KDEL (SEQ ID NO:13).

14. The immunogen of claim 1 which has an amino acid sequence selected  
15 from:

PE (SEQ ID NO:2) except that amino acids 361-384 are substituted with the amino acid sequence: Gly Ala Ala Asn Leu His Cys Gly Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Cys Met Gln Gly Pro Ala Asp (SEQ ID NO:7) and amino acid Glu at position 553 is deleted (ntPE-V3MN14), and

20 PE (SEQ ID NO:2) except that amino acids 361-384 are substituted with the amino acid sequence: Gly Ala Ala Asn Leu His Cys Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn Ile Ile Gly Thr Ile Cys Met Gln Gly Pro Ala Asp (SEQ ID NO:8) and amino acid Glu at position 553 is deleted (ntPE-V3MN26).

25 15. The immunogen of claim 1 wherein the non-native epitope is an epitope from a viral, bacterial or parasitic protozoan pathogen.

16. The immunogen of claim 9 wherein the non-native epitope is an epitope of a V3 loop of gp120 of HIV-1.

17. The immunogen of claim 9 wherein the non-native epitope is an epitope of a principal neutralizing loop of a retrovirus.

18. The immunogen of claim 9 wherein the non-native epitope is an epitope of a major neutralizing loop of HIV-2 or a V3 loop of gp120 of HIV-1 of at least 8 amino acids including a V3 loop apex.

19. A recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

20. The recombinant polynucleotide of claim 19 which is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

21. The recombinant polynucleotide of claim 19 wherein the nucleotide sequence encodes the amino acid sequence of PE wherein domain Ib of PE further comprises the non-native epitope between two cysteine residues of domain Ib and wherein amino acid Glu at position 553 is deleted.

22. A recombinant non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen cloning platform comprising a nucleotide sequence encoding: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence and (4) a splicing site between the sequence encoding the translocation domain and the sequence encoding the ER retention domain.



23. The recombinant cloning platform of claim 22 which is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

24. A method of producing antibodies against a non-native epitope,  
5 wherein the non-native epitope naturally exists within a cysteine-cysteine loop comprising the step of inoculating an animal with a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence  
10 of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising a cysteine-cysteine loop that contains within the loop an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

15 25. The method of claim 24 wherein the cysteine-cysteine loop comprises no more than about 30 amino acids.

26. The method of claim 24 wherein the non-native epitope is an epitope of the V3 domain of HIV-1.

27. A vaccine comprising at least one non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell  
20 recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that  
25 encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

28. The vaccine of claim 27 comprising a plurality of PE-like chimeric immunogens, each immunogen having a different non-native epitope.

29. The vaccine of claim 27 further comprising a pharmaceutically acceptable carrier.

30. The vaccine of claim 27 in the form of an immunization dose wherein the immunogen is present in an amount effective to elicit in a human subject an immune response against the non-native epitope.

31. The vaccine of claim 28 wherein the different non-native epitopes are epitopes of different strains of the same pathogen.

32. The vaccine of claim 31 wherein the non-native epitope is an epitope of the V3 loop of HIV-1 and the different strains of the same pathogen are HIV-1 MN and HIV-1 Thai-E.

33. A method of eliciting an immune response against a non-native epitope in a subject, the method comprising the step of administering to the subject a vaccine comprising at least one non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

34. The method of claim 33 wherein the non-native epitope comprises a binding motif for an MHC Class II molecule of the subject and the immune response elicited is an MHC Class-II dependent cell-mediated immune response.

35. The method of claim 33 wherein the non-native epitope comprises a binding motif for an MHC Class I molecule of the subject and the immune response elicited is an MHC Class-I dependent cell-mediated immune response.

36. The method of claim 33 wherein the non-native epitope is an epitope of the V3 domain of HIV-1.

37. The method of claim 33 wherein the vaccine is administered as a prophylactic treatment against a disease mediated by an agent bearing the non-native epitope.

38. The method of claim 33 wherein the vaccine is administered as a therapeutic treatment against a disease mediated by an agent bearing the non-native epitope.

5                   39. A polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence  
10 substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

15                   40. A method of eliciting an immune response against a non-native epitope in a subject, the method comprising the step of administering to the subject a polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of  
20 between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER")  
25 retention domain that comprises an ER retention sequence.

41. The method of claim 40 wherein the recombinant polynucleotide is an expression vector comprising an expression control sequence operatively linked to the nucleotide sequence.

42. The method of claim 40 wherein the nucleotide sequence further encodes a mammalian secretory sequence attached to the amino terminus of the immunogen.

43. A method of eliciting an immune response against a non-native epitope in a subject, the method comprising the steps of transfecting cells with a recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence, and administering the cells to the subject.

# INTERNATIONAL COOPERATION TRL

LDV  
JRS

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

59 JUN -2 AM 8:44  
RECEIVED

PCT

WRITTEN OPINION

(PCT Rule 66)

To:  
STORELLA, John R. et al.  
TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center  
8th Floor  
San Francisco, CA 94111  
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 2 5. 05. 99

Applicant's or agent's file reference  
15280-3101PC

REPLY DUE within 3 month(s)  
from the above date of mailing

International application No.  
PCT/US98/14341

International filing date (day/month/year)  
10/07/1998

Priority date (day/month/year)  
11/07/1997

International Patent Classification (IPC) or both national classification and IPC  
C12N15/62

Applicant  
THE GOVERNMENT OF THE UNITED STATES as ...et al.

1. This written opinion is the first drawn up by this International Preliminary Examining Authority.

8.25.99

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain document cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 11/11/1999.

JRS  
DD  
DOCKETED

Name and mailing address of the international preliminary examining authority:

 European Patent Office  
D-80298 Munich  
Tel. (+49-89) 2399-0 Tx: 523656 epmu d  
Fax: (+49-89) 2399-4465

Authorized officer / Examiner

Kalsner, I

Formalities officer (incl. extension of time limits)  
Vullo, C

Telephone No. (+49-89) 2399 8061



doctored - emg

## WRITTEN OPINION

International application No. PCT/US98/14341

### I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"*):

#### Description, pages:

1-62 as originally filed

#### Claims, No.:

1-43 as originally filed

#### Drawings, sheets:

1/14-14/14 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

### V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

#### 1. Statement

Novelty (N)	Claims	(1-43: yes)
Inventive step (IS)	Claims	(1-43: yes)
Industrial applicability (IA)	Claims	(1-43: yes)

#### 2. Citations and explanations

see separate sheet

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**Ad Section V: Reasoned statement with regard to novelty, inventive step or industrial applicability**

**1) Documents**

D1...EP-A-0439954

**2) Novelty and inventive step**

The present international application relates to a non-toxic *Pseudomonas* exotoxin A-like chimeric immunogen comprising a cell recognition domain that binds to a cell surface receptor, a translocation domain, a non-native epitope domain and a ER retention domain and to a recombinant polynucleotide encoding such protein. The recombinant chimeric protein or the polynucleotide encoding the chimeric protein are employed in methods of producing antibodies, methods of eliciting an immune response and in vaccines.

D1 is considered to represent the closest prior art. It discloses non-toxic hybrid proteins comprising a cell-binding ligand and a translocation domain of *Pseudomonas* exotoxin A and a non-native epitope domain. The chimeric protein disclosed in D1 is used to target a non-native epitope (such as e.g. enzyme, antibiotic, antigen, etc.) to a specific cell recognised by the cell binding ligand.

The difference between the present application and the disclosure of D1 lies in the structure of the chimeric protein (the hybrid of D1 does not include an ER retention signal) as well as in the intended applications of the chimeric protein.

The problem to be solved by the present application is to provide a hybrid protein in which an immunogenic epitope is included in order to elicit an immune response to this epitope.

Non of the available prior art discloses or suggests chimeric proteins as claimed in the present application. **Claims 1-43** are thus considered to meet the requirements of Art. 33(2) and (3) PCT.



- 3) **Claims 24-26, 33-38 and 40-43** are directed to a method of treatment of the human or animal body. In this respect the following should be noted:

For the assessment of these claims on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Ad Section VIII: Certain observations on the international application**

The present application does not meet the requirements of Art. 6 PCT for the following reasons:

**Claim 2** is not clear as it refers to an amino acid sequence of PE $\Delta$ E553. PE $\Delta$ E553 is considered an arbitrary designation which is without meaning for the skilled person.

**Claim 12**, too, is not clear in the sense of Art. 6 PCT, because "the mutation  $\Delta$ E553" is not defined and thus is meaningless.

**Claim 14** refers to the immunogen of claim 1 merely by arbitrary designation. The terms ntPE-V3MN14 and ntPE-V3MN26 are meaningless to a skilled person and are therefore unclear.

**Claim 21** does not meet the requirements of Art. 6 PCT as it refers to a recombinant polynucleotide "having the amino acid sequence ...".

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>15280-3101PC</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 98/ 14341</b>	International filing date (day/month/year) <b>10/07/1998</b>	(Earliest) Priority Date (day/month/year) <b>11/07/1997</b>
Applicant  <b>THE GOVERNMENT OF THE UNITED STATES as ....et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☒ **Certain claims were found unsearchable**(see Box I).
2. ☐ **Unity of invention is lacking**(see Box II).
3. ☒ The international application contains disclosure of a **nucleotide and/or amino acid sequence listing** and the international search was carried out on the basis of the sequence listing
  - ☐ filed with the international application.
  - ☒ furnished by the applicant separately from the international application.
    - ☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
  - ☐ Transcribed by this Authority
4. With regard to the title, ☒ the text is approved as submitted by the applicant
  - ☐ the text has been established by this Authority to read as follows:
5. With regard to the abstract,
  - ☒ the text is approved as submitted by the applicant
  - ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:
  - Figure No. 1 ☐ as suggested by the applicant. ☐ None of the figures.
  - ☒ because the applicant failed to suggest a figure.
  - ☐ because this figure better characterizes the invention.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 14341

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 24-26, 33-38, and 40-43  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/14341

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 A61K39/21 C07K16/10 A61K39/104 C12N15/70  
A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>EP 0 439 954 A (SERAGEN, INC.) 7 August 1991</p> <p>see page 2, line 45 - page 3, line 50 see page 4, line 1 - line 40 see page 5, line 23 - line 53 see page 11, line 35 - page 12, line 26 --- -/--</p>	<p>1-5, 7, 8, 12, 15-20, 22-24, 26-43</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 October 1998

Date of mailing of the international search report

10/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/14341

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>VIJAY . CHAUDHARY ET AL.: "Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,</p> <p>vol. 87, no. 1, January 1990, pages 308-312, XP002079997</p> <p>WASHINGTON US</p> <p>see abstract</p> <p>see page 308, right-hand column, paragraph 2</p>	<p>1,3-5,7, 8,15-20, 22-24, 26-43</p>
Y	<p>MAJA LUKAC ET AL.: "Toxoid of Pseudomonas aeruginosa Exotoxin A generated by deletion of an active site residue"</p> <p>INFECTION AND IMMUNITY.,</p> <p>vol. 56, no. 11, November 1988, pages 3095-3098, XP002080494</p> <p>WASHINGTON US</p> <p>see abstract</p>	<p>2,12</p>
A	<p>S.J. CRYZ JR ET AL.: "Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine"</p> <p>VACCINE.,</p> <p>vol. 13, no. 1, January 1995, pages 67-71, XP002079998</p> <p>GUILDFORD GB</p> <p>cited in the application</p> <p>see abstract</p> <p>see page 67, left-hand column, paragraph 1 - right-hand column, paragraph 1</p> <p>see page 69, left-hand column, paragraph 2</p> <p>see page 70, right-hand column, paragraph 2 - page 71, left-hand column, paragraph 1</p>	
P,X	<p>DAVID J. FITZGERALD ET AL.: "Characterization of V3 loop-Pseudomonas Exotoxin chimeras"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY,</p> <p>vol. 273, no. 16, 17 April 1998, pages 9951-9958, XP002079999</p> <p>MD US</p> <p>see the whole document</p>	<p>1-43</p>
T	<p>WO 98 20135 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA) 14 May 1998</p> <p>see page 4, line 4 - line 32</p> <p>see page 22, line 40 - line 50</p> <p>see page 23, line 22 - page 25, line 2</p> <p>see page 27, line 18 - page 29, line 5</p> <p>see page 31, line 2 - page 32, line 12</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/14341

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 439954	A	07-08-1991	AU 657087 B	02-03-1995
			AU 7168991 A	24-07-1991
			AU 8032194 A	27-04-1995
			CA 2071969 A	23-06-1991
			JP 5502880 T	20-05-1993
			WO 9109871 A	11-07-1991
			US 5668255 A	16-09-1997
<hr/>				
WO 9820135	A	14-05-1998	AU 5247498 A	29-05-1998
<hr/>				

WHAT IS CLAIMED IS:

1. A non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.
2. The immunogen of claim 1 having the amino acid sequence of PE (SEQ ID NO:2) except that the sequence of domain Ib comprises the non-native epitope between two cysteine residues of domain Ib and amino acid Glu at position 553 is deleted.
3. The immunogen of claim 1 wherein the cell recognition domain is domain Ia of PE.
4. The immunogen of claim 1 wherein cell recognition domain binds to  $\alpha$ 2-macroglobulin receptor (" $\alpha$ 2-MR"), epidermal growth factor ("EGF") receptor; the IL-2 receptor; the IL-6 receptor; HIV-infected cells; a chemokine receptor; a leukocyte cell surface receptor; a ligand for the IgA receptor; or an antibody or antibody fragment directed to a receptor.
5. The immunogen of claim 1 wherein cell recognition domain comprises amino acid sequences of a growth factor or an antibody. 6. The immunogen of claim 1 wherein cell recognition domain is comprised within the ER retention domain.
7. The immunogen of claim 1 wherein the translocation domain comprises amino acids 280 to 364 of domain II of PE.
8. The immunogen of claim 1 wherein the translocation domain is domain II of PE.

9. The immunogen of claim 1 wherein the non-native epitope domain comprises a cysteine-cysteine loop that comprises the non-native epitope.

10. The immunogen of claim 1 wherein the non-native epitope domain comprises an amino acid sequence encoding a non-native epitope inserted between two  
5 cysteine residues of domain Ib of PE.

11. The immunogen of claim 1 wherein the non-native epitope domain comprises an amino acid sequence selected from CTRPNYNKRK RIHIGPGRAF YTTKNIIGTI RQAHC (SEQ ID NO:3) or CTRPSNNTRT SITIGPGQVF YRTGDIIGDI RKAYC (SEQ ID NO:4).

10 12. The immunogen of claim 1 wherein the ER retention domain is domain III of PE except that amino acid Glu at position 553 of SEQ ID NO:2 is deleted.

13. The immunogen of claim 1 wherein the ER retention sequence comprises REDLK (SEQ ID NO:11), REDL (SEQ ID NO:12) or KDEL (SEQ ID NO:13).

14. The immunogen of claim 1 which has an amino acid sequence selected  
15 from:

PE (SEQ ID NO:2) except that amino acids 361-384 are substituted with the amino acid sequence: Gly Ala Ala Asn Leu His Cys Gly Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Cys Met Gln Gly Pro Ala Asp (SEQ ID NO:7) and amino acid Glu at position 553 is deleted (ntPE-V3MN14), and

20 PE (SEQ ID NO:2) except that amino acids 361-384 are substituted with the amino acid sequence: Gly Ala Ala Asn Leu His Cys Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys Asn Ile Ile Gly Thr Ile Cys Met Gln Gly Pro Ala Asp (SEQ ID NO:8) and amino acid Glu at position 553 is deleted (ntPE-V3MN26).

25 15. The immunogen of claim 1 wherein the non-native epitope is an epitope from a viral, bacterial or parasitic protozoan pathogen.

16. The immunogen of claim 9 wherein the non-native epitope is an epitope of a V3 loop of gp120 of HIV-1.



17. The immunogen of claim 9 wherein the non-native epitope is an epitope of a principal neutralizing loop of a retrovirus.

18. The immunogen of claim 9 wherein the non-native epitope is an epitope of a major neutralizing loop of HIV-2 or a V3 loop of gp120 of HIV-1 of at least 8 amino acids including a V3 loop apex.

19. A recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

20. The recombinant polynucleotide of claim 19 which is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

21. The recombinant polynucleotide of claim 19 wherein the nucleotide sequence encodes the amino acid sequence of PE wherein domain Ib of PE further comprises the non-native epitope between two cysteine residues of domain Ib and wherein amino acid Glu at position 553 is deleted.

22. A recombinant non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen cloning platform comprising a nucleotide sequence encoding: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence and (4) a splicing site between the sequence encoding the translocation domain and the sequence encoding the ER retention domain.

23. The recombinant cloning platform of claim 22 which is an expression vector further comprising an expression control sequence operatively linked to the nucleotide sequence.

24. A method of producing antibodies against a non-native epitope,  
5 wherein the non-native epitope naturally exists within a cysteine-cysteine loop comprising the step of inoculating an animal with a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a  
10 translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising a cysteine-cysteine loop that contains within the loop an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

15 25. The method of claim 24 wherein the cysteine-cysteine loop comprises no more than about 30 amino acids.

26. The method of claim 24 wherein the non-native epitope is an epitope of the V3 domain of HIV-1.

27. A vaccine comprising at least one non-toxic *Pseudomonas* exotoxin A-  
20 like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that  
25 encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

28. The vaccine of claim 27 comprising a plurality of PE-like chimeric immunogens, each immunogen having a different non-native epitope.

29. The vaccine of claim 27 further comprising a pharmaceutically acceptable carrier.

30. The vaccine of claim 27 in the form of an immunization dose wherein the immunogen is present in an amount effective to elicit in a human subject an immune  
5 response against the non-native epitope.

31. The vaccine of claim 28 wherein the different non-native epitopes are epitopes of different strains of the same pathogen.

32. The vaccine of claim 31 wherein the non-native epitope is an epitope of the V3 loop of HIV-1 and the different strains of the same pathogen are HIV-1 MN and  
10 HIV-1 Thai-E.

33. A method of eliciting an immune response against a non-native epitope in a subject, the method comprising the step of administering to the subject a vaccine comprising at least one non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of  
15 between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER")  
20 retention domain that comprises an ER retention sequence.

34. The method of claim 33 wherein the non-native epitope comprises a binding motif for an MHC Class II molecule of the subject and the immune response elicited is an MHC Class-II dependent cell-mediated immune response.

35. The method of claim 33 wherein the non-native epitope comprises a  
25 binding motif for an MHC Class I molecule of the subject and the immune response elicited is an MHC Class-I dependent cell-mediated immune response.

36. The method of claim 33 wherein the non-native epitope is an epitope of the V3 domain of HIV-1.

37. The method of claim 33 wherein the vaccine is administered as a prophylactic treatment against a disease mediated by an agent bearing the non-native epitope.

38. The method of claim 33 wherein the vaccine is administered as a therapeutic treatment against a disease mediated by an agent bearing the non-native epitope.

5                   39. A polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence  
10 substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence.

15                   40. A method of eliciting an immune response against a non-native epitope in a subject, the method comprising the step of administering to the subject a polynucleotide vaccine comprising at least one recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of  
20 between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER")  
25 retention domain that comprises an ER retention sequence.

41. The method of claim 40 wherein the recombinant polynucleotide is an expression vector comprising an expression control sequence operatively linked to the nucleotide sequence.

42. The method of claim 40 wherein the nucleotide sequence further encodes a mammalian secretory sequence attached to the amino terminus of the immunogen.

43. A method of eliciting an immune response against a non-native epitope in a subject, the method comprising the steps of transfecting cells with a recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic *Pseudomonas* exotoxin A-like ("PE-like") chimeric immunogen, the PE-like chimeric immunogen comprising: (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor; (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol; (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope; and (4) an amino acid sequence encoding an endoplasmic reticulum ("ER") retention domain that comprises an ER retention sequence, and administering the cells to the subject.